

Best Available Copy

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|--|
| <p>(51) International Patent Classification ⁶ : A61K 38/17, C07K 14/435, C12N 15/00, 15/12</p> | <p>A1</p> | <p>(11) International Publication Number: WO 95/17905 (43) International Publication Date: 6 July 1995 (06.07.95)</p> |
| <p>(21) International Application Number: PCT/US94/14431 (22) International Filing Date: 29 December 1994 (29.12.94) (30) Priority Data: 08/176,126 29 December 1993 (29.12.93) US (60) Parent Application or Grant (63) Related by Continuation US 08/176,126 (CIP) Filed on 29 December 1993 (29.12.93) (71) Applicant (for all designated States except US): WAKE FOR- EST UNIVERSITY [US/US]; Medical Center Boulevard, Winston-Salem, NC 27157-1023 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): DAWSON, Paul, A. [US/US]; 2111 Carriage Way, Chapel Hill, NC 27514 (US). (74) Agents: PARKER, David, L. et al.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).</p> | | <p>(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ). Published With international search report.</p> |
| <p>(54) Title: ILEAL BILE ACID TRANSPORTER COMPOSITIONS AND METHODS (57) Abstract Bile acids are absorbed from the small intestine by a passive and an active mechanism. The active mechanism involves a Na⁺/bile acid cotransporter. A cDNA encoding the ileal bile acid cotransporter from both hamster and human have been isolated and sequenced. The amino acid sequences of the cotransporter proteins are also disclosed. The renal bile acid cotransporter is also shown to be identical to the ileal cotransporter. The cotransporters disclosed herein will have use in treatment of hypercholesterolemia, diabetes, heart disease and liver disease. In addition, methods of screening man made and naturally occurring substances for the discovery of new bile acid transport inhibitors and activators and methods of detecting mutations and sequence length polymorphisms in human ileal/renal bile acid transporter genes are disclosed.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria | GB | United Kingdom | MR | Mauritania |
| AU | Australia | GE | Georgia | MW | Malawi |
| BB | Barbados | GN | Guinea | NE | Niger |
| BE | Belgium | GR | Greece | NL | Netherlands |
| BF | Burkina Faso | HU | Hungary | NO | Norway |
| BG | Bulgaria | IE | Ireland | NZ | New Zealand |
| BJ | Benin | IT | Italy | PL | Poland |
| BR | Brazil | JP | Japan | PT | Portugal |
| BY | Belarus | KE | Kenya | RO | Romania |
| CA | Canada | KG | Kyrgyzstan | RU | Russian Federation |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan |
| CG | Congo | KR | Republic of Korea | SE | Sweden |
| CH | Switzerland | KZ | Kazakhstan | SI | Slovenia |
| CI | Côte d'Ivoire | LI | Liechtenstein | SK | Slovakia |
| CM | Cameroon | LK | Sri Lanka | SN | Senegal |
| CN | China | LU | Luxembourg | TD | Chad |
| CS | Czechoslovakia | LV | Latvia | TG | Togo |
| CZ | Czech Republic | MC | Monaco | TJ | Tajikistan |
| DE | Germany | MD | Republic of Moldova | TT | Trinidad and Tobago |
| DK | Denmark | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | US | United States of America |
| FI | Finland | MN | Mongolia | UZ | Uzbekistan |
| FR | France | | | VN | Viet Nam |
| GA | Gabon | | | | |

- 1 -

DESCRIPTIONILEAL BILE ACID TRANSPORTER

5

COMPOSITIONS AND METHODSBACKGROUND OF THE INVENTION

10 The government owns rights in the present invention pursuant to grant number DK08718 from the National Institutes of Health.

1. Field of the Invention

15

 The present invention relates generally to the fields of sodium/bile acid cotransport systems in the ileum and kidney. Certain embodiments of the invention relate to the medically related fields of the control of blood cholesterol levels and treatments of diabetes, heart disease, liver disease and various digestive disorders. More particularly, the invention concerns the isolation and purification of bile acid cotransporter proteins and cDNA clones encoding the proteins and the use of these proteins and nucleic acids in therapeutic, preventative, genetic counseling and reagent screening applications.

25

2. Description of the Related Art

30

 Bile acids are acidic sterols synthesized from cholesterol in the liver. Following synthesis, the bile acids are secreted into bile and enter the lumen of the small intestine, where they facilitate absorption of fat-soluble vitamins and cholesterol. Bile acids are then absorbed from the small intestine, returned to the liver via the portal circulation, and resecreted into bile. In

35

- 2 -

the small intestine, bile acids are absorbed by both passive and active mechanisms (Dietschy, 1968). The active absorption of bile acids, first described by Lack and Weiner (1961), has been shown in man and experimental
5 animals to be restricted to the ileum (Krag and Phillips, 1974; Schiff et al., 1972; Lack, 1979).

The first step in the active uptake of bile acids is mediated by a Na^+ gradient-driven transporter located at
10 the brush border (apical) membrane of the ileocyte (Wilson, 1981). Once inside the enterocyte, bile acids are transported across the cell to the basolateral membrane and secreted into the portal circulation via a Na^+ -independent organic anion exchange system (Weinberg
15 et al., 1986). The transport kinetics and specificity of this Na^+ /bile acid cotransport system have been studied extensively using everted ileal gut sacs (Schiff et al., 1972; Lack, 1979), isolated ileocytes (Wilson et al., 1975; Schwenk et al., 1983), and ileal brush border
20 membranes (Barnard and Ghishan, 1987; Kramer et al., 1992; Wilson and Treanor, 1979).

Although the mechanism of ileal bile acid transport has been characterized, the protein(s) responsible for
25 this process have not been isolated and characterized. In an attempt to identify the proteins involved, photoaffinity studies have been performed using radiolabeled 7,7'-azo-derivatives of taurocholate with ileocytes and ileocyte membrane fractions (Kramer et.
30 al., 1983; Lin et. al., 1990). These studies tentatively identified a brush border (apical) membrane protein of 99 kDa and basolateral membrane proteins of 54 and 59 kDa. More recently, lysylglycocholate-Sepharose affinity chromatography was used to isolate bile acid transporter-
35 enriched ileal brush border membranes for polyclonal antibody production. In immunoblotting experiments, these antibodies detected a number of proteins including

- 3 -

a 99 kDa protein in rat ileal brush border and kidney proximal tubule membranes. These antibodies also partially inhibited bile acid transport by isolated ileal brush border membranes (Gong et al., 1991). The tentative identification of a 90-99 kDa protein is also supported by chemical modification studies in rabbit ileum where agents that inhibited bile acid transport into ileal brush border membrane vesicles also blocked photoaffinity labeling of a 90 kDa protein (Kramer et al., 1992).

Notably lacking with the lysylglycocholate-Sepharose affinity chromatography and photoaffinity labeling studies was functional reconstitution of bile acid transport activity. Several candidate bile acid binding proteins previously identified by photoaffinity labeling have since been abandoned, illustrating the difficulties with this technique. For example, candidate 67 kDa and 43 kDa proteins were later shown to be albumin and actin, respectively (Fricker et al., 1982). Also, a candidate 54 kDa protein for the hepatic Na⁺-independent multispecific anion transporter, has recently been shown to be Protein Disulfide Isomerase (Peter Meier, personal communication). The multispecific transporter has since been identified by expression cloning in *Xenopus* oocytes and shown to be a 75 kDa protein (Jacquemin et al., 1992).

Based on these observations, the 54 kDa protein identified in ileal basolateral membranes by photoaffinity labeling (Lin et al., 1988) may also be Protein Disulfide Isomerase. In addition, a candidate 49 kDa protein for the hepatic Na⁺-dependent sinusoidal membrane bile acid transporter has been shown to be microsomal epoxide hydrolase (Von Dippe et al., 1993). Whereas the relationship between microsomal epoxide hydrolase and bile acid transport is still unclear, a

- 4 -

candidate 40 kDa membrane glycoprotein with bile acid transport properties has independently been identified by expression cloning in *Xenopus* oocytes (Hagenbuch et al., 1991). Unfortunately, the identity of the ileal bile acid transporter has remained elusive because it has not been purified to homogeneity and functionally reconstituted or identified by cloning and expression.

The enterohepatic circulation of bile acids serves as a continuous link between the liver and small intestine. Disturbances in this cycling of bile acids have dramatic physiological consequences for both organ systems and for cholesterol homeostasis (Hofmann, 1989). This is illustrated by common disturbances of bile acid circulation including cholestasis and intestinal malabsorption. In addition to steatorrhea, bile acid malabsorption also has severe consequences for the colon, where excess bile acid results in watery diarrhea. Whereas the etiology of the bile acid malabsorption is clear in cases of ileal resection or Crohn's disease, specific defects in ileal bile acid transport or its regulation may also be responsible for some cases of chronic idiopathic diarrhea (Read et al., 1980; Heubi et al., 1981).

Bile acid malabsorption or disruption of the bile acid enterohepatic circulation stimulates *de novo* synthesis of bile acids in the liver. This results in an increased demand for cholesterol by the liver, which is compensated for by enhanced clearance of plasma LDL as well as increased hepatic cholesterol synthesis. If the malabsorption is significant, hepatic bile acid production may be unable to compensate for the loss, resulting in decreased intraluminal bile acid concentrations and a reduced ability to solubilize and absorb biliary and dietary cholesterol. This is the basis for the decreased plasma cholesterol levels and

- 5 -

reduced morbidity from cardiovascular disease associated with ileal resection in the POSCH study (Program on the Surgical Control of Hyperlipidemias; Buchwald et al., 1990).

5

A less radical approach to treatment is the ingestion of polymeric bile acid sequestrants, such as cholestyramine and colestipol. Disruption of the bile acid enterohepatic circulation, especially in combination with HMG CoA reductase inhibitors, increases the number of hepatic LDL receptors and thereby decreases plasma LDL cholesterol levels (Brown and Goldstein, 1986). Despite gaps in the understanding of hepatic synthesis or intestinal conservation of bile acids, this drug regimen is widely used for the treatment of many forms of hypercholesterolemia (Goodman et al., 1988). Based on its remarkable substrate specificity, the ileal Na⁺- dependent system represents an attractive target for treatment of hypercholesterolemia by interruption of the enterohepatic circulation with specific inhibitors of bile acid transport.

Therefore, bile acid transporter inhibitors are another immediate need in the art, which has not been met because the purified transporter is not available. Previous attempts to design inhibitors relied on the use of intact laboratory animals, isolated small intestine or kidney tissue, or isolated intestinal enterocytes. The use of laboratory animals instead of tissue culture cells or purified bile acid transporter enzyme made large scale drug screens prohibitively cumbersome and expensive. The number of compounds which could be assayed was also limited with small intestinal sections or isolated enterocytes, which are difficult to prepare and viable for only a period of hours.

- 6 -

Obviously, one would like to use the human ileal and renal bile acid transporters in these drug screens in the event that the animal model does not accurately mimic the human condition. However, human tissue is not readily available and very few human intestinal or kidney cell lines which express bile acid transporter activity exist. Currently, a human colon cancer cell line (CaCo₂) has been discovered which expresses very small amounts of bile acid transporter activity. Unfortunately, this cell line requires special culture conditions and would be difficult to adapt to a high throughput assay format.

Therefore, there exists a need for a purified bile acid transporter to be used in the diagnosis and treatment of numerous human and animal conditions which are affected by this important system. In addition, a purified transporter would have utility in the screening of natural and man made products with possible pharmaceutical properties in the treatment of cholesterol related diseases and digestive and hepatic disorders.

SUMMARY OF THE INVENTION

The present invention seeks to overcome these and other drawbacks inherent in the prior art by providing the first definitive identification and isolation of mammalian ileal bile acid transporters. With the use of the present invention, high levels of bile acid transporter activity can be expressed in transfected tissue culture cells or in prokaryotic cells. In addition, cell lines which permanently express high levels of the transporter can be readily generated and used, for example in a high throughput assay to rapidly screen for inhibitors of the bile acid transporter.

- 7 -

In certain embodiments the present invention is a segment of nucleic acid and particularly a segment of nucleic acid comprising an isolated gene encoding a mammalian ileal/renal bile acid cotransporter polypeptide and preferably a mammalian ileal/renal bile acid cotransporter comprising an amino acid sequence in accordance with the amino acid sequence as set forth herein as SEQ ID NO:2 and SEQ ID NO:4. This DNA segment may also comprise the nucleic acid sequence as set forth herein as SEQ ID NO:1 or SEQ ID NO:3 or it may have the sequence designated herein as SEQ ID NO:1 or SEQ ID NO:3. In addition, a mammalian ileal/renal bile acid cotransporter coding sequence, wherein the sequence hybridizes to the sequence of SEQ ID NO:1 or SEQ ID NO:3 under stringent conditions is also an embodiment of the present condition. In this use of the word stringent, the hybridization of a related gene, such as a mammalian liver bile acid transporter would be excluded, but related ileal/renal bile acid transporters would hybridize. An example of such conditions would include hybridization in 50% formamide buffer, followed by washing in 0.2 X SSC at 65°C for 30 minutes. It is understood that in addition to the DNA sequence coding strand, the complement of the coding sequence, the RNA sequence encoded by the DNA segment and the complement of the RNA sequence are also encompassed by the present claimed invention.

As used herein the term "complement" is used to define the strand of nucleic acid which has the complementary sequence of a first nucleic acid sequence. Alternatively, the complementary strand is one that will hybridize to the first nucleic acid sequence to form a double stranded molecule under stringent conditions. Stringent conditions are those that allow hybridization between two nucleic acid sequences with a high degree of homology, but precludes hybridization of random or low

- 8 -

homology sequences. For example, hybridization at low temperature and/or high ionic strength is termed low stringency and hybridization at high temperature and/or low ionic strength is termed high stringency. The temperature and ionic strength of a desired stringency are understood to be applicable to particular probe lengths, to the length and base content of the sequences and to the presence of formamide in the hybridization mixture.

10

It is understood in the art that a nucleic acid sequence will hybridize with a complementary nucleic acid sequence under high stringency conditions even though some mismatches may be present. Such closely matched, but not perfectly complementary sequences are also encompassed by the present invention. For example, differences may occur through genetic code degeneracy, or by naturally occurring or man made mutations, deletions or insertions and such mismatched sequences would still be encompassed by the present claimed invention.

20

It is also understood that the nucleic acid segment of the present invention may be positioned under the control of a promoter. The promoter may be the normal promoter which controls the expression of the nucleic acid segment in its native tissue, or it may be a recombinant promoter. By recombinant promoter is meant a promoter derived from another source, either another within the same cell or from a different type of cell or even from a different organism. The promoter sequence is then joined to the nucleic acid segment in an upstream position (5') from the start of the gene. Preferred promoters are cytomegalovirus major immediate early gene promoter, simian virus 40 late gene promoter and Baculovirus *Autographa californica* nuclear polyhedrosis virus polyhedrin gene promoter. Alternatively, the promoter may be an inducible promoter such as the lactose

35

- 9 -

operon promoter. It is also understood that the promoter may also comprise an enhancer region and that promoter as used herein also encompasses any necessary enhancers.

5 The nucleic acid segment of the present invention may also comprise a vector capable of replicating within a cell. In particular, the nucleic acid segment may comprise a recombinant vector. A large number of vectors are available commercially and are well known to those in
10 the art. In general, a vector is compatible with a particular cell type such as prokaryotic, eukaryotic, yeast, plant, insect, etc. The matching of compatible vectors and host cells is well known and routinely practiced in the art. Preferred vectors in the practice
15 of the present invention are pCMX and pCMV5.

 In certain embodiments, the present invention is a recombinant cell or a recombinant host cell, which
 comprises a recombinant nucleic acid segment encoding a
20 mammalian ileal/renal bile acid cotransporter, and wherein said recombinant DNA segment may be positioned in a recombinant vector. As used herein, the term
 "engineered" or "recombinant" cell is intended to refer to a cell into which a recombinant gene, such as a gene
25 encoding a bile acid cotransporter has been introduced. Therefore, engineered cells are distinguishable from naturally occurring cells which do not contain a recombinantly introduced gene. Engineered cells are thus
 cells having a gene or genes introduced through the hand
30 of man. Recombinantly introduced genes will either be in the form of a cDNA gene (i.e., they will not contain introns), a copy of a genomic gene, or will include genes positioned adjacent to a promoter not naturally
 associated with the particular introduced gene. The
35 recombinant cells of the invention may be prokaryotic or eukaryotic cells and preferred cell lines to be used in

- 10 -

the present invention are CHO cells, MDCK, CaCo₂ and BHK cells, and more preferred are COS-1A cells.

5 The vector which comprises the nucleic acid segment
of the present invention may also be an expression
vector. In this embodiment, the nucleic acid segment
encoding the ileal/renal bile acid cotransporter will be
transcribed into mRNA and the mRNA will be translated
10 into a polypeptide. Thus, the recombinant cell will
express the ileal/renal bile acid cotransporter
polypeptide and may comprise a nucleic acid sequence in
accordance with the sequences designated herein as SEQ ID
NO:1 or SEQ ID NO:3. The vector in this embodiment may
15 comprise the signal sequences necessary to express the
gene in the particular cell type. For instance the
promoter/enhancer regions, translational start sites and
downstream signals such as the polyadenylation site if
necessary, will be compatible with the host cell
transcription/translational mechanisms.

20

It is understood that smaller nucleic acid segments
which comprise as their nucleic acid sequence part or all
of the nucleic acid sequence of SEQ ID NO:1 or SEQ ID
NO:3 are also encompassed by the present invention. For
25 example, nucleic acid segments comprising at least a ten,
fifteen, seventeen, twenty, twenty-five, thirty, fifty,
one hundred, one thousand, one thousand forty four, one
thousand forty seven or even up to a two thousand two
hundred and sixty three nucleotide long stretch which
30 corresponds to the nucleic acid sequence of SEQ ID NO:1
or SEQ ID NO:3 and including the nucleic acid sequence of
SEQ ID NO:1 or SEQ ID NO:3 are also a part of and are
included in the present claimed invention. These
segments are understood to be contiguous segments with
35 the same or complementary sequences to contiguous
segments of the disclosed sequences, SEQ ID NO:1 or SEQ
ID NO:3.

- 11 -

The recombinant host cell which comprises a vector and expresses the ileal/renal bile acid cotransporter, may be further defined as comprising a nucleic acid fragment of up to 10,000, up to 5,000 or up to 3,000 basepairs in length. It may alternatively be defined as comprising a nucleic acid fragment of up to 1,000, up to 500, up to 100 or even up to 50 basepairs in length. The vector may be an RNA molecule or more preferably a DNA molecule. It is also understood that the nucleic acid segments, vectors and host cells comprising a nucleic acid segment described herein may comprise a DNA segment or an RNA segment.

In certain alternate embodiments, the present invention is a polypeptide, a protein, or even a peptide, comprising an amino acid sequence as set forth in SEQ ID NO:2 or SEQ ID NO:4, or even a polypeptide or protein with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or consisting essentially of the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4. It is also understood that amino acid fragments or peptides of the present invention will have utility, for example as antigenic epitopes, in the production of antibodies or as screening agents. The identification of such epitopic sequences is well known in the art and would be available to one of skill in light of the present disclosure.

In particular, the Kyte-Doolittle hydropathy profile would give guidance to one of skill in the art to design antigenic peptides derived from the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4. Therefore, a peptide or polypeptide which comprises an antigenic amino acid sequence derived from the sequence of SEQ ID NO:2 or SEQ ID NO:4 would be encompassed by the claimed invention. For example, an antigenic amino acid sequence of at least ten amino acids stretch or a fifteen amino acid stretch which corresponds to at least a ten or fifteen amino acid

- 12 -

stretch of SEQ ID NO:2 or SEQ ID NO:4 would also be an embodiment of the present invention. In particular, an amino acid segment with the sequence disclosed herein as SEQ ID NO:5 and shown to be immunoreactive would be an
5 embodiment of the invention.

An important use of the peptide fragments of the present invention is the production of antibodies which are immunoreactive with said peptides or polypeptides.
10 These antibodies will have wide utility as diagnostic agents for the various disorders discussed in the present disclosure as well as use as possible inhibitors of bile acid transport. Therefore antibodies which are produced with the peptides or polypeptides of the present
15 invention, or those antibodies which are found to be immunoreactive with the peptides or polypeptides of the present invention are also a part of this invention. The antibodies may be polyclonal antibodies or monoclonal antibodies and may be derived from any source such as
20 goat, mouse, bovine, equine, simian or any other source, even including recombinantly produced antibodies. The production of anti-idiotypic antibodies is also well known in the art, and any such anti-idiotypic antibodies are also encompassed by the present invention. In a
25 preferred embodiment, an antibody of the present invention may be an antibody immunoreactive with a peptide having the amino acid sequence designated herein as SEQ ID NO:5.

30 An important embodiment of the present invention is a method of screening substances as modulators of ileal/renal bile acid cotransport. The discovery of the nucleic acid and amino acid sequences of the present invention provides a new and valuable method of screening
35 naturally occurring and man made substances for their ability to inhibit or even to stimulate or activate ileal and/or renal bile acid cotransport. By the use of the

- 13 -

present invention, and particularly by the use of recombinant cells which express the ileal/renal bile acid cotransporter, a high throughput assay is possible for the first time.

5

This screening assay comprises obtaining a candidate substance and determining an effect of the candidate substance on cotransport activity. The candidate substance can come from any source. For example, it is proposed that compounds isolated from natural sources such as fungal extracts, plant extracts, bacterial extracts, higher eukaryotic cell extracts, or even extracts from animal sources, or marine, forest or soil samples, may be assayed for the presence of potentially useful pharmaceutical agents. In addition, man made substances which would include, but are not limited to, synthetic bile acid derivatives, peptides or other compounds designed *de novo* based on the predicted protein structure of the ileal/renal bile acid cotransporter, can also be screened for possible use as pharmaceutical agents. It is also understood that antibodies and other isolated or purified, but naturally occurring compounds could be screened by this process.

25

In a preferred screening process, recombinant cells expressing the ileal/renal bile acid cotransporter may be deposited on a surface such as the wells of a microtiter plate or in any suitable medium or container. A substrate to indicate cotransport would also be present in contact with the cells. A preferred substrate is ^3H -taurocholate in the presence of sodium ions, but other substances or taurocholate labelled by other means or even unlabelled and alternate cations are also possible and would fall within the scope of the present invention. Some distinguishable groups of cells would then be exposed to the candidate substance and some would not be so exposed. A measurement of the taurocholate uptake,

30

35

- 14 -

for example would then be compared between cells which were or were not incubated with the candidate substance. An increase in uptake over the control would indicate an activating substance and a decrease in uptake over the control would indicate an inhibitor and no difference would indicate a substance that is not a modulator.

It is understood that the inhibition or activation could occur at any level of the expression of bile acid cotransport, including gene transcription, RNA processing, mRNA translation, post translational modification and even protein transport or at any other level that would have the overall effect of activation or inhibition of bile acid transport. Preferred cells to be used in the assay would be Chinese hamster ovary cells (CHO) for example, however, any cells which express the ileal/renal bile acid cotransporter would be acceptable and would be encompassed by the present claimed invention. Examples of useful cell types include MDCK, CaCo₂, BHK, COS AND 293 cells.

An aspect of the present invention may also be described as a method of screening substances as modulators of ileal/renal bile acid cotransporter expression comprising obtaining a candidate substance, exposing cells expressing a reporter gene under the control of an ileal or renal bile acid cotransporter promoter to said candidate substance and determining an effect of said candidate substance upon expression of said reporter gene. In this embodiment, the reporter gene under the control of an ileal or renal bile acid cotransporter promoter would be expressed in cells in the presence and absence of a candidate substance as in the previously described screening assays. A change in level of the reporter gene product in the presence of the candidate substance relative to the level in the absence of the candidate substance would indicate an effector of

- 15 -

bile acid transporter expression. Preferred reporter genes include, but are not limited to the β -galactosidase gene from *E. coli* and chloramphenicol acetyltransferase.

5 The present invention also encompasses a method of detecting ileal/renal bile acid cotransporter nucleic acid comprising obtaining a nucleic acid sample suspected of containing ileal/renal bile acid cotransporter nucleic acid and detecting the presence of ileal/renal bile acid
10 cotransporter nucleic acid in the sample. This method may comprise obtaining a cDNA library from ileal or renal tissue of a subject and hybridizing the library to a nucleic acid segment of the present invention. A clone from the library that hybridizes may then be amplified
15 using primers sequences disclosed herein or by any other means and determining the genetic sequence of the amplified segment. In certain preferred embodiments, the nucleic acid sample is from a human subject and the
20 nucleic acid segment used to probe the library is a sequence according to SEQ ID NO:3.

 A method of detecting heterozygous ileal/renal bile acid cotransporter gene alleles in a subject comprising amplifying the ileal/renal bile acid cotransporter genes
25 from said subject and subjecting the amplified nucleic acid segments to denaturation followed by electrophoresis under nondenaturing conditions is also an embodiment of the present invention. This method may also be used to detect inactive ileal/renal bile acid cotransporter gene
30 alleles. A variation in the nucleic acid sequence of a subjects alleles will cause a polymorphism in the annealed nucleic acid segments and the polymorphism will be visible upon gel electrophoresis under nondenaturing conditions as an extra band. In a preferred embodiment,
35 this method is used to detect a mutation at position 290 in which the proline is changed to serine. The present method is preferably practiced by amplifying with the

- 16 -

polymerase chain reaction using oligonucleotides having the sequences of SEQ ID NO:6 and SEQ ID NO:7 as primers, or alternatively using oligonucleotides having the sequences of SEQ ID NO:8 and SEQ ID NO:9 as primers.

5

Another use of the present invention is a method of identifying polymorphic alleles of the ileal/renal bile acid cotransporter of a subject. This method comprises obtaining a genomic library; identifying clones encoding the ileal/renal bile acid cotransporter by amplification using nucleic acid segments disclosed herein as polymerase chain reaction primers; hybridizing oligonucleotides comprising labelled dinucleotide repeat sequences to said clones under conditions to selectively hybridize to dinucleotide repeat sequences in order to identify said repeat sequences linked to said ileal/renal bile acid cotransporter; determining the gene sequence in the flanking areas of the dinucleotide repeat; synthesizing oligonucleotide primers complementary to said flanking areas capable of amplifying said dinucleotide repeat sequences; obtaining genomic DNA from said subject; amplifying said DNA from said subject with said oligonucleotide primers; and determining the size of the amplified DNA. In a preferred practice of this method, the subject is a human and the subject's genomic DNA is amplified by using oligonucleotide sequences SEQ ID NO:10 and SEQ ID NO:11.

While certain aspects of the invention may have human clinical uses, the invention of the present disclosure will also find use in the practice of veterinary pharmacology and in the screening of animal diseases and gastrointestinal disorders in addition to its use in diagnoses and screening of human genetic disorders and in the discovery and formulation of transport effectors.

- 17 -

ABBREVIATIONS

The following abbreviations are used throughout the present disclosure:

5
IBAT, ileal Na⁺/bile acid cotransporter; LBAT, liver Na⁺/bile acid cotransporter; GAPD: glyceraldehyde-3-phosphate dehydrogenase; TEA: tetraethylammonium; BSP, bromosulphophthalein; DIDS, 4,4'-diisothiocyano-2,2'-
10 disulfonic acid stilbene; TC: taurocholate; GC: glycocholate; TCDC: taurochenodeoxycholate; TDC: taurodeoxycholate; SDS: sodium dodecyl sulfate.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention
20 may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

FIG. 1A. Expression cloning of ileal Na⁺/bile acid
25 cotransporter. For each transfection experiment, 10 to 24 pools of cDNA plasmids were transiently transfected into duplicate dishes of COS cells. The horizontal axis denotes cDNA plasmid pools of approximately 3000 clones each. The activity is expressed as [³H]taurocholate
30 uptake relative to pCMV-βgal transfected COS cells. [³H]taurocholate uptake into pCMV-βgal transfected cells was 1.56 ± 0.52 pmoles hour⁻¹ mg⁻¹ protein (n = 17).

FIG. 1B. Purification of the pIBAT cDNA clone. Positive
35 pool 41-1 was subdivided into 18 pools, of which the data for subfraction 7 (S7) is shown. Positive pool 41-1/S7 was subdivided into 48 pools, of which the data for

- 18 -

subfraction 15 is shown. Two hundred colonies from subpool 41-1/S7/15 were randomly picked and plated onto two 10 X 10 matrices. Pools of cDNA plasmids were prepared from bacterial cultures of each row (1-20) and each column (1-20) and assayed for [³H]taurocholate uptake. Four positive pools were identified, and the data is shown for column 13, row 13, as well as the single clone at the intersection of column 13 and row 13 (C13/R13). [³H]taurocholate uptake into control DNA transfected cells was 0.98 ± 0.29 pmoles hour⁻¹ mg⁻¹ protein (n = 10). As a positive control, [³H]taurocholate uptake for COS cells transfected with 2 ng of pCMV-LBAT plus 2 μ g of pCMV- β gal is shown.

FIG. 2. Hydropathy plot of amino acid sequences of the hamster ileal and rat liver Na⁺/bile acid cotransporters. Increasing numerical values correspond to increased hydrophobicity. The residue specific hydropathy index was calculated over a window of 11 residues by the method of Kyte and Doolittle (1982) using the Genetics Computer Group Sequence Analysis Software Package, Version 7.1 (Devereux et al., 1984). The plot shows an alignment of amino acids 1-348 of IBAT and amino acids 1-343 of LBAT. For maximal alignment, a gap of 5 amino acids was inserted at the amino terminus of the LBAT sequence. The X axis refers to the amino acid residue number in the IBAT sequence.

FIG. 3. Blot hybridization of mRNA from hamster tissues. Poly(A)⁺ RNA (5 μ g) from the indicated tissues was subjected to electrophoresis on a 1.2% agarose gel containing 2.2 M formaldehyde and blotted onto a GeneScreen membrane (Dupont-NEN). *Upper panel*, hybridization was carried out in 50% formamide buffer at 42°C for 11 hours with a mixture of three single-stranded uniformly ³²P-labeled IBAT cDNA probes (4.2×10^6 cpm/ml). The filter was washed in 0.2 X SSC containing 0.1% (w/v)

- 19 -

SDS at 65°C for 30 minutes and exposed to Amersham Hyperfilm with an intensifying screen for 12 hours at -70°C. The migration of RNA standards run in an adjacent lane are indicated. Lower panel, the filter was stripped and rehybridized with a uniformly ^{32}P -labeled human glyceraldehyde-3-phosphate dehydrogenase probe (GAPD; 1×10^7 cpm/ml), washed, and exposed to Amersham Hyperfilm for 1 hour at -70°C.

FIG. 4. Sodium-dependence of taurocholate uptake in IBAT-transfected COS cells. On day 0, dishes of 1.50×10^6 COS cells per 100-mm dish were plated in medium A. On day 1, cells were transfected with 5 μg of pIBAT or pCMV- βgal plasmid by the DEAE-dextran method. On day 2, each group of transfected cells was trypsinized, pooled, and replated in 24 well culture plates at 7×10^4 cells/well. On day 4, the cells were incubated with medium C supplemented with 5 μM [^3H]taurocholate (2.0 Ci/mmol) and containing 137 mM sodium or equal concentrations of tetraethylammonium, potassium, or choline. After 15 minutes at 37°C, the medium was removed, and each cell monolayer washed and processed to determine cell-associated protein and radioactivity. Taurocholate uptake in the presence of 137 mM sodium was set at 100% and all values are graphed relative to this level. The "100% of control" value was 134 ± 26 pmoles $\text{min}^{-1} \text{mg}^{-1}$ protein ($n=10$).

FIG. 5A. Kinetics of taurocholate uptake in pIBAT-transfected COS cells. COS cells were plated and transfected as described in the description of FIG. 4 (immediately above). On day 4, the cells were incubated in medium B supplemented with the indicated concentration of [^3H]taurocholate (45 mCi/mmol). After 15 minutes at 37°C, the medium was removed, and each cell monolayer washed and processed to determine cell-associated protein and radioactivity. Activity is reported as [^3H]

- 20 -

taurocholate uptake (pmol/min/mg) at indicated levels of [^3H] taurocholate (μM). Each value represents the mean \pm standard deviation ($n = 4$).

- 5 FIG. 5B. Eadie-Hofstee analysis of taurocholate uptake in pIBAT-transfected COS cells. The uptake data from FIG. 5A was analyzed and revealed a K_m for taurocholate uptake of 33 μM and a V_{max} of 396 pmol min $^{-1}$ mg $^{-1}$ protein.

10

- FIG. 6A. Transport specificity of pIBAT-transfected COS cells in the presence of competitors. COS cells were plated and transfected as described in the description of FIG. 4 (immediately above). On day 4, the cells were
15 incubated in medium B supplemented with 5 μM [^3H]taurocholate (2.0 Ci/mmol) in the presence or absence of 50 μM unlabeled competitor. TC: taurocholate, GC: glycocholate, TCDC: taurochenodeoxycholate, TDC: taurodeoxycholate. Taurocholate uptake in the absence of
20 competitor was set at 100% and all values are graphed relative to this level. The "100% of control" value was 36.1 \pm 3.7 pmoles min $^{-1}$ mg $^{-1}$ protein. Each bar represents the mean \pm standard deviation ($n=6$).

- 25 FIG. 6B. Transport specificity of pIBAT-transfected COS cells in the presence of inhibitor. COS cells were plated and transfected as described in the description of FIG. 4 (immediately above). On day 4, the cells were incubated in medium B supplemented with 5 μM
30 [^3H]taurocholate (2.0 Ci/mmol) in the presence or absence of 100 μM unlabeled inhibitor. Taurocholate uptake in the absence of inhibitor was set at 100%, as described in the description of FIG. 6A (immediately above), and all values are graphed relative to that level. The "100% of
35 control" value was 90.7 \pm 11.9 pmoles min $^{-1}$ mg $^{-1}$ protein. Each bar represents the mean \pm standard deviation ($n=6$).

- 21 -

FIG. 7A. An antibody was made to a synthetic peptide corresponding to amino acids 335-348 (SEQ ID NO:5) of the hamster ileal Na⁺/bile acid cotransporter as described in Example V. To demonstrate the specificity of the antibody, 100 µg of rat jejunal or ileal brush border membrane protein was denatured and reduced in Laemmli sample buffer containing 2% (w/v) SDS and 2.5% (v/v) β-mercaptoethanol. The protein was then subjected to electrophoresis on a 10% SDS-polyacrylamide gel and stained with coomassie blue.

FIG. 7B. Protein prepared in FIG. 7A transferred to a nitrocellulose filter and immunoblotted.

FIG. 8. The deduced amino acid sequences of the human IBAT (HIBAT, SEQ ID NO:4) and hamster IBAT (SEQ ID NO:2) were compared and sequence differences are boxed. Overall, the hamster and human ileal bile acid transporter sequences exhibit 84% identity and 90% similarity.

FIG. 9. Taurocholate uptake in human ileal bile acid transporter-transfected COS cells: Effect of a naturally occurring mutation at amino acid 290. On day 0, dishes of 5 x 10⁵ COS cells/60 mm dish were plated in DMEM (HG) containing 10% (v/v) fetal calf serum, 100 units/ml penicillin and 100 µg/ml streptomycin. On day 1, cells were transfected by the DEAE-dextran method with 2 µg of either pCMV-βgal, pCMX-IBAT, pCMV-HIBAT(P/S) encoding a serine at position 290, or pCMV-HIBAT which encodes a proline residue at position 290. On day 4, the cells were incubated with a modified Hanks balanced salt solution containing 5 µM [³H]taurocholate (2.1 Ci/mmol) and 0.2% (w/v) bovine serum albumin. After incubating for 15 min. at 37°C, the medium was removed and the cell monolayer was washed five times with ice-cold phosphate-buffered saline plus 0.2% (w/v) bovine serum albumin and

- 22 -

then once with ice-cold phosphate-buffered saline alone. Cell monolayers were lysed in 0.1 N NaOH and aliquots were taken to determine cell-associated protein and radioactivity. The data is reported as [³H]taurocholate uptake relative to pCMV- β gal transfected COS cells.

FIG. 10. Topology model for the human ileal/renal bile acid transporter. The deduced amino acid sequence (SEQ ID NO:4) and predicted secondary structure for the human ileal/renal bile acid transporter is shown. The circled residues are those which differ between the human (SEQ ID NO:4) and hamster (SEQ ID NO:2) bile acid transporter amino acid sequences. The boxed residues represent predicted transmembrane domains I through VII. The small circles represent a potential N-linked glycosylation site. The serine substitution for a proline at position 290 is indicated by a box and arrow.

FIG. 11A. Effect of Sodium Concentration on Taurocholate Uptake in HIBAT-Transfected COS Cells. Activity is reported as [³H] taurocholate uptake (pmol/min/mg) as a function of NaCl concentration (mM).

FIG. 11B. Hill plot analysis of the data from FIG. 11A indicating that the coupling between Na⁺ and taurocholate is 1:1.

FIG. 12. Data indicating the uptake of [³H] taurocholate in CHO cell lines, 9-4-10-1, 9-4-10-2 and 9-4-10-7 stably expressing HISBT.

FIG. 13A. Graphic showing the positions of the PCR primers flanking the region of amino acid 290 (arrow).

FIG. 13B. SSCP analysis of P₂₉₀ > S₂₉₀ mutation after amplification with primers HIBAT-12 (SEQ ID NO:8) and HIBAT-13 (SEQ ID NO:9).

- 23 -

FIG. 14. Summary of Crohn's disease study. Lanes 5-14 are individuals identified in the study as having a heterozygous mutation in the ileal bile acid transporter gene. Lane 4 is a positive control from patient SH. Lanes 1-3 and 15-16 are from patients lacking the mutation.

FIG. 15. The pedigree and SSCP analysis of a family with Crohn's disease (dark squares). The gel lanes are directly under the individuals in the family tree from whom the samples were taken.

FIG. 16 This gel is a summary of $(CA)_n$ alleles linked to HISBT in CEPH parents. Numbers 1 through 9 above the lanes indicate the polymorphic alleles discovered by this method.

FIG 17. Fluorescence *in situ* hybridization of human ISBT probe (long arrow) to human metaphase chromosomes localizes the ileal Na^+ /bile acid cotransporter gene to chromosome band 13q33. Inset, fluorescent *in situ* cohybridization of human ISBT probe (long arrow) and Retinoblastoma probe (triangle marker) to human chromosome 13.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Active uptake of bile acids from the lumen of the small intestine is mediated by an ileal Na^+ -dependent bile acid transport (IBAT) system. To identify components of this transport system, an expression cloning strategy was employed to isolate a hamster ileal cDNA that exhibits bile acid transport activity. By Northern blot analysis, mRNA for the cloned transporter was readily detected in ileum and kidney but absent from liver and proximal small intestine.

- 24 -

It was found that the transporter cDNA encoded a 348 amino acid protein with seven potential transmembrane domains and three possible N-linked glycosylation sites. The amino acid sequence was 35% identical and 63% similar to the rat liver Na⁺/bile acid cotransporter (LBAT, Hagenbuch et al., 1991). IBAT exhibited little sequence identity with the Na⁺/glucose cotransporter or other members of the large family of 12 transmembrane domain Na⁺ cotransport proteins (Wright et al., 1992).

Hydropathy analysis of the sequences from the LBAT and IBAT transporters predicted a similar topology with seven transmembrane domains, an extracellular amino terminus, and a cytosolic carboxyl terminus. Both LBAT and IBAT were also found to lack the predicted Na⁺ binding motif which had been identified in a number of 12 transmembrane domain Na⁺ cotransport proteins (Deguchi et al., 1990; Wright et al., 1992). Overall, the predicted topology for IBAT showed greater similarity to the seven transmembrane domain proteins, such as rhodopsin and G protein coupled receptors (Khorana, 1992; Baldwin, 1993).

The amino acid homology between the liver and ileal Na⁺/bile acid cotransport proteins is clustered in both the predicted transmembrane domains and the cytoplasmic and exoplasmic loops. For example, a repeated motif is found in the second and third predicted transmembrane domains of both proteins. A block of sequence identity also exists in the putative extracellular loop that lies between the sixth and seventh transmembrane domains. The hamster IBAT cDNA encodes three potential N-linked glycosylation sites. Interestingly, the two N-linked glycosylation sites adjacent to the initiator methionine are conserved between the liver and ileal bile acid transporters. Preliminary studies by the inventor using an *in vitro* translation/translocation system (Blobel and Dobberstein, 1975) indicate that IBAT is modified by N-

- 25 -

linked glycosylation. The utilization of particular glycosylation sites as well as the contribution of the conserved amino acid domains to transporter function are yet to be determined.

5

In agreement with the properties described for ileal bile acid transport (Wilson, 1981), the isolated IBAT clone exhibited uptake activity that was Na⁺-dependent, saturable, and bile acid-specific. Using an everted gut
10 sac model (Lack, 1979), ileal bile acid uptake has been studied extensively and found to specifically require Na⁺ ions. A similar Na⁺ requirement was also demonstrated for IBAT, where taurocholate uptake was stimulated over 100-fold in the presence of Na⁺ but not other cations
15 (see FIG. 4).

In addition, taurocholate uptake by the expressed IBAT was saturable and exhibited an apparent Km of 33 μ M. This Km was similar to the values of 36, 37, and 65 μ M
20 reported for taurocholate uptake by rabbit ileal brush border membranes, human ileal brush border membranes, and CaCo₂ cells, respectively (Kramer et al., 1992; Barnard and Grishan, 1987; Chandler et al., 1993). Like these in vitro measurements, the apparent Km for taurocholate
25 transport in pIBAT-transfected COS cells was considerably less than the apparent Km of 5-10 mM determined for taurocholate uptake using *in situ* ileal preparations (Lewis and Root, 1990; Marcus et al., 1991). One
30 possible explanation for these differences may be the presence of a diffusion barrier such as the mucous layer that is present in the intact intestine but absent in isolated cells and membranes (Wilson and Dietschy, 1974).

In the studies of transport specificity, dihydroxy
35 bile acids such as taurochenodeoxycholic acid and taurodeoxycholic acid were more effective competitors of [³H]taurocholate uptake by IBAT-transfected COS cells

- 26 -

than the trihydroxy bile acid, taurocholate. These results were similar to those obtained using everted ileal gut sacs and *in situ* perfusions (Lack, 1979; Schiff et al., 1972). In addition, as reported for rabbit ileal
5 brush border membrane vesicles (Kramer et al., 1992), taurocholate uptake by IBAT was not inhibited by the cholephilic organic compound, bromosulfophthalein (BSP) or the bifunctional anion transport inhibitor 4,4'-diisothiocyano-2,2'-disulfonic acid stilbene (DIDS).

10

By Northern blot analysis, IBAT mRNA was found in intestinal regions and tissues known to express Na⁺/bile acid cotransport activity. Under stringent conditions, the IBAT cDNA hybridized to mRNA from hamster kidney as
15 well as ileum, suggesting that IBAT may also be responsible for the Na⁺/bile acid cotransport activity present in the renal tubules (Weiner et al., 1964; Wilson et al., 1981).

20

In the intestine, IBAT mRNA expression was restricted to the ileum and distal jejunum. These results are consistent with a large number of studies using perfused intestine, perfused intestinal sections, everted gut sacs, isolated enterocytes, and isolated
25 enterocyte brush border membranes which identified the distal ileum as the major site of Na⁺-dependent bile acid uptake in the intestine (Hofmann, 1977; Wilson, 1981). These results are also consistent with *Xenopus* oocyte expression studies, where mRNA for Na⁺/bile acid
30 cotransporter activity was detected in ileum but not duodenum or jejunum from rabbit and guinea pig (Sorscher et al., 1992). Interestingly however, *Xenopus* oocyte injection experiments using pig intestine mRNA detected Na⁺/bile acid cotransporter mRNA in proximal as well as
35 distal intestine (Mullins et al., 1992). While the basis for this species difference in the intestinal gradient of bile acid transporter expression is unknown, the

- 27 -

availability of an ileal Na⁺/bile acid cotransporter cDNA should facilitate the study of its expression down the cephalocaudal axis of the intestine in different species.

5 The Na⁺-dependence, saturability, and bile acid specificity of transport, as well as the tissue specificity of mRNA, indicates that the IBAT cDNA described herein does express the Na⁺/bile acid cotransporter activity previously described in ileum
10 (Hofmann, 1977, Wilson, 1981). The isolated transporter cDNA clone encodes a protein of 348 amino acids with an approximate molecular mass of 38 kDa, and three potential N-linked glycosylation sites. This molecular mass clearly differs from the 90 and 99 kDa proteins
15 previously identified by affinity labeling using photolabile derivatives of taurocholate (Lin et al., 1990; Kramer et al., 1992). The relationship between IBAT and the photoaffinity labeled proteins is unclear. The 90 to 99 kDa protein may represent a
20 posttranslationally modified form of the 38 kDa Na⁺/bile acid cotransporter or possibly a dimer which is poorly dissociated by SDS polyacrylamide gel electrophoresis. For example, the seven transmembrane domain protein, rhodopsin, is known to form dimers and oligomers that are
25 refractory to dissociation under the denaturing and reducing conditions used for SDS polyacrylamide gel electrophoresis (DeGrip, 1982; Fliesler and Basinger, 1985). Alternatively, it is possible that ileal enterocytes harbor more than one brush border membrane
30 Na⁺/bile acid cotransporter.

 With the availability of a cDNA encoding an active ileal Na⁺/bile acid cotransporter, it is now possible to express large amounts of the cotransporter in cultured
35 cells. This ability will allow the molecular mechanism of ileal bile acid transport to be elucidated. This information will be crucial for the design of inhibitors

- 28 -

and possibly useful mutations of the cotransporter. Further, it is now possible to examine the relationship between the protein encoded by this cDNA and proteins which have been identified by other means and which may be involved in bile acid transport.

Expression of Bile Acid Transporter Activity

The present technology utilizes ileal enterocytes isolated from laboratory animals. These preparations express high levels of transport activity (>1000 pmoles of taurocholate transported per minute per mg of cell protein) but are viable for very short periods of time (1-6 hours). The bile acid transporter-transfected tissue culture cells of the present invention express similar levels of bile acid transport activity (600 to 1000 pmoles of taurocholate transported per minute per mg of cell protein), and can be passaged in culture for months.

20

Present technology also utilizes a human colon carcinoma-derived cell line, CaCo₂ cells. While these cells can be passaged for weeks, CaCo₂ cells require specialized culture conditions to express their ileal cell and bile acid transporter properties. In addition, CaCo₂ cells only weakly express bile acid transport activity (approximately 10 pmoles of taurocholate transported per minute per mg of cell protein). This activity is 60 to 100-fold less than the activity of bile acid transporter-transfected tissue culture cells of the present invention. Recent improvements in CaCo₂ cell culture conditions have substantially increased their bile acid transport activity (Chandler et al., 1993). However, the culture conditions required are cumbersome and the high levels of activity are limited to certain clonal lines within a narrow window of cell passages. The present invention overcomes these restrictions.

- 29 -

The isolation of the cDNA segment of the present invention will allow the expression of large quantities of the ileal/renal bile acid transporter protein in various expression vectors and host cells. Examples of appropriate expression systems include, but are not limited to bacterial expression of recombinant plasmids and/or phage, recombinant baculovirus-infected insect cells and mammalian tissue culture cells such as Chinese hamster ovary (CHO) cells. The ileal/renal bile acid transporter cDNA may also be used for stable expression of the ileal/renal bile acid transporter protein in transgenic animals such as mice.

Since the isolated cDNAs encompass the entire coding sequence, one may proceed to prepare an expression system for the preparation of recombinant ileal/renal bile acid cotransporter. The engineering of DNA segment(s) for expression in a prokaryotic or a eukaryotic system may be performed by techniques generally known to those of skill in recombinant expression. It is believed that virtually any expression system may be employed in the expression of the ileal/renal bile acid cotransporter.

Prokaryotic hosts may be preferred for expression of the ileal/renal bile acid cotransporter for some applications. Some examples of prokaryotic hosts are various *E. coli* strains, bacilli such as *Bacillus subtilis*, or other enterobacteriaceae such as *Salmonella typhimurium* or *Serratia marcescens*, and various *Pseudomonas* species may be used, with *E. coli* being the most preferred.

In general, plasmid vectors containing replicon and control sequences which are derived from species compatible with the host cell are used in connection with these hosts. The vector ordinarily carries a replication site, as well as marking sequences which are capable of

- 30 -

providing phenotypic selection in transformed cells. For example, a well known plasmid useful for transforming *E. coli* is pBR322, a plasmid derived from an *E. coli* species. pBR322 contains genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells. The pBR plasmid, or other microbial plasmid or phage must also contain, or be modified to contain, promoters which can be used by the microbial organism for expression of its own proteins.

10

In addition, phage vectors containing replicon and control sequences that are compatible with the host microorganism can be used as transforming vectors in connection with these hosts. For example, the phage lambda pGEMTM-11 may be utilized in making a recombinant phage vector which can be used to transform host cells, such as *E. coli* LE392. The most preferred prokaryotic vectors include pKK233-2, which utilizes the strong IPTG-inducible P_{trc} promoter and the pT7 series which utilize the T7 RNA polymerase promoter system.

15
20

Some promoters commonly used in recombinant DNA construction include the B-lactamase (penicillinase) and lactose promoter systems, as well as viral promoters. While these are the most commonly used, other microbial promoters have been discovered and utilized, and details concerning their nucleotide sequences are readily available, enabling a skilled worker to ligate them functionally into plasmid vectors.

25
30

In addition to prokaryotes, eukaryotic microbes, such as yeast cultures may also be used. *Saccharomyces cerevisiae*, or common baker's yeast is a commonly used eukaryotic microorganism, although a number of other strains are available. For expression in *Saccharomyces*, the plasmid YRp7, for example, may be used. This plasmid contains the *trp1* gene which provides a selection marker

35

- 31 -

for a mutant strain of yeast lacking the ability to grow in tryptophan. The presence of the *trp1* lesion as a characteristic of the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan.

Suitable promoting sequences in yeast vectors include the promoters for 3-phosphoglycerate kinase or other glycolytic enzymes such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. In constructing suitable expression plasmids, the termination sequences associated with these genes are also ligated into the expression vector 3' of the expressed sequence to provide polyadenylation of the mRNA and termination. Other promoters, which have the additional advantage of transcription controlled by growth conditions are the promoter region for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, the aforementioned glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Any plasmid vector containing a yeast-compatible promoter, an origin of replication, and termination sequences is suitable.

Of particular interest is the use of insect cells as a host for baculoviral expression vectors. Currently, the preferred baculovirus expression systems utilize the lytic insect virus known as *Autographa californica* multiply enveloped nuclear polyhedrosis virus. For production of recombinants in insect cells using recombinant baculoviral vectors, it is desirable to utilize the polyhedron gene's powerful promoter and control sequences. This can be accomplished by replacing

- 32 -

the baculoviral polyhedrin gene with the cDNA to be expressed. Baculoviral expression vectors ordinarily include all the original baculoviral genes except the polyhedrin gene and may include additional marker genes such as the β -galactosidase gene. Examples of such useful baculoviral preparations include Linearized AcMNPV Baculovirus DNA, Linearized AcRP23.lacZ Baculovirus DNA, and Linearized AcUW1.lacZ Baculovirus DNA. After cloning the cDNA to be expressed in a suitable transfer plasmid, the cDNA can be transferred in place of the baculovirus polyhedrin gene by the process of recombination. The transfer plasmids contain baculoviral DNA sequences to promote the recombination with linear baculoviral DNA and may also contain additional marker genes such as the β -galactosidase gene. Suitable transfer plasmids include pBlueBac III, pBlueBacHis, and pAcUW21. The recombination to assemble the recombinant baculovirus which expresses the cDNA of interest and production of the protein product from that cDNA is performed in insect cells or insect hosts. Examples of suitable host cells include *Spondoptera frugiperda* Sf9 cells, Sf21 cells, and MG1 cells.

In addition to microorganisms and insects, cultures of cells derived from vertebrate organisms may also be used as hosts. In principle, any such vertebrate or invertebrate cell culture is workable. However, vertebrate cells are a preferred host, and propagation of vertebrate cells in culture (tissue culture) has become a routine procedure in recent years. Examples of such useful host cell lines are VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, and W138, BHK, COS-7, 293 and MDCK cell lines. Expression vectors for such cells ordinarily include (if necessary) an origin of replication, a promoter located in front of the gene to be expressed, along with any necessary ribosome binding

- 33 -

sites, RNA splice sites, polyadenylation site, and transcriptional terminator sequences.

For use in mammalian cells, the control functions on the expression vectors are often provided by viral material. For example, commonly used promoters are derived from polyoma, cytomegalovirus, Adenovirus 2, and most frequently Simian Virus 40 (SV40). The early and late promoters of SV40 virus are particularly useful because both are obtained easily from the virus as a fragment which also contains the SV40 viral origin of replication. Smaller or larger SV40 fragments may also be used, provided there is included the approximately 250 bp sequence extending from the Hind III site toward the Bgl I site located in the viral origin of replication. Further, it is also possible, and often desirable, to utilize promoter or control sequences normally associated with the desired gene sequence, provided such control sequences are compatible with the host cell systems.

20

The origin of replication may be provided either by construction of the vector to include an exogenous origin, such as may be derived from SV40 or other viral (e.g., Polyoma, Adeno, VSV, BPV) source, or may be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often sufficient.

25

It is understood in the art that to bring a coding sequence under the control of a promoter, one positions the 5' end of the transcription initiation site of the transcriptional reading frame of the protein between about 1 and about 50 nucleotides "downstream" of (i.e., 3' of) the chosen promoter. In addition, where eukaryotic expression is contemplated, one will also typically desire to incorporate into the transcriptional unit which includes the cotransporter protein, an

30

35

- 34 -

appropriate polyadenylation site (e.g., 5'-AATAAA-3') if one was not contained within the original cloned segment. Typically, the poly A addition site is placed about 30 to 2000 nucleotides "downstream" of the termination site of the protein at a position prior to transcription termination.

It is contemplated that the ileal/renal bile acid cotransporter of the invention may be "overexpressed", i.e., expressed in increased levels relative to its natural expression in ileal or renal cells, or even relative to the expression of other proteins in the recombinant host cell. Such overexpression may be assessed by a variety of methods, including radio-labelling and/or protein purification. However, simple and direct methods are preferred, for example, those involving SDS/PAGE and protein staining or Western blotting, followed by quantitative analyses, such as densitometric scanning of the resultant gel or blot. A specific increase in the level of the recombinant protein or peptide in comparison to the level in natural ileal or renal cells is indicative of overexpression, as is a relative abundance of the specific protein in relation to the other proteins produced by the host cell as determined, e.g., by visibility on a gel.

Generally speaking, it may be more convenient to employ as the recombinant gene a cDNA version of the gene. It is believed that the use of a cDNA version will provide advantages in that the size of the gene will generally be much smaller and more readily employed to transfect the targeted cell than will a genomic gene, which will typically be up to an order of magnitude larger than the cDNA gene. However, the inventor does not exclude the possibility of employing a genomic version of a particular gene where desired.

- 35 -

Amino Acid Segments

An important embodiment of the amino acid sequences of the present invention is the use of the ileal/renal bile acid transporter amino acid sequence to model the protein structure for use in inhibitor design, for example. Initially, this entails a comparison of the protein sequence disclosed herein with the sequences of related proteins. In this way, the transmembrane domains and the putative glycosylation sites have been determined. Also, by comparing the amino acid sequence of the present disclosure with proteins of similar function (bile acid binding, cotransport, etc.) sequences may be identified which are directly involved in those functions. In particular, amino acid residues which are conserved over a range of species are good candidates for involvement in functional active sites or binding sites. The amino acid sequence of the bile acid transporter will thus be useful for designing superior inhibitors. For example, potential inhibiting substances can be tested for binding to amino acid segments known to be involved in various functions of the cotransporter, and would thus be screened for potential inhibition of activity.

An alternate use of the ileal/renal bile acid transporter protein sequence will be to model the protein structure for use in designing compounds as vehicles for drug targeting. For example, bile acid analogues have been recently used as targeting agents to direct drug delivery specifically to the liver or ileum. Drugs such as HMG CoA reductase inhibitors were coupled to a bile acid analog and shown to be specifically and efficiently taken up by the liver. Analogous systems can be designed for use with the ileal/renal transporter, and the sequences of the present invention will be useful for designing these new drug delivery vehicles.

- 36 -

Production of Antibodies

Another important embodiment of the amino acid sequences of the ileal bile acid transporter is their use in the production of antibodies. This amino acid sequence has been used to synthesize a peptide as antigen for monospecific antibody development. For example, the peptide, Ser-Phe-Gln-Glu-Thr-Asn-Lys-Gly-Phe-Gln-Pro-Asp-Glu-Lys, (SEQ ID NO:5), which corresponds to amino acids 335-348 of the hamster ileal/renal bile acid transporter has been used successfully as antigen for monospecific antibody development. The cDNA clone has also been used to express portions of the ileal bile acid transporter in bacteria as antigen for monospecific antibody development.

Antibodies, both polyclonal and monoclonal, specific for the bile acid cotransporter of the present invention may be prepared using conventional immunization techniques, as will be generally known to those of skill in the art. A composition containing antigenic epitopes of the bile acid cotransporter can be used to immunize one or more experimental animals which will then proceed to produce specific antibodies against the bile acid cotransporter protein. Typically an animal used for production of antisera is a rabbit, a mouse, a rat, a hamster or a guinea pig. Because of the relatively large blood volume of rabbits, a rabbit is a preferred choice for production of polyclonal antibodies. Polyclonal antisera may be obtained, after allowing time for antibody generation, simply by bleeding the animal and preparing serum samples from the whole blood.

As is well known in the art, a given polypeptide may vary in its immunogenicity. It is often necessary therefore to couple the immunogen (e.g., a polypeptide of the present invention) with a carrier. Exemplary and

- 37 -

preferred carriers are keyhole limpet hemocyanin (KLH), Purified Peptide Derivative of Tuberculin (PPD) and bovine serum albumin (BSA). Other albumins such as ovalbumin, mouse serum albumin or rabbit serum albumin can also be used as carriers. Means for conjugating a polypeptide to a carrier protein are well known in the art and include glutaraldehyde, m-maleimidobencoyl-N-hydroxysuccinimide ester, carbodiimide and bis-biazotized benzidine. As is also well known in the art, immunogenicity to a particular immunogen can be enhanced by the use of non-specific stimulators of the immune response known as adjuvants. Exemplary and preferred adjuvants include complete Freund's adjuvant, incomplete Freund's adjuvants and aluminum hydroxide adjuvant.

The amount of immunogen used in the production of polyclonal antibodies depends *inter alia*, upon the nature of the immunogen as well as the animal used for immunization. A variety of routes can be used to administer the immunogen (subcutaneous, intramuscular, intradermal, intravenous and intraperitoneal). The production of polyclonal antibodies is monitored by sampling blood of the immunized animal at various points following immunization. When a desired level of immunogenicity is obtained, the immunized animal can be bled and the serum isolated and stored.

A monoclonal antibody of the present invention can be readily prepared through use of well-known techniques such as those exemplified in U.S. Pat. No 4,196,265, incorporated herein by reference. Typically, a technique involves first immunizing a suitable animal with a selected antigen (e.g., a polypeptide of the present invention) in a manner sufficient to provide an immune response. Rodents such as mice and rats are preferred animals. Spleen cells from the immunized animal are then fused with cells of an immortal myeloma cell. Where the

- 38 -

immunized animal is a mouse, a preferred myeloma cell is a murine NS-1 myeloma cell, and a more preferred cell line is the NS1/1 Ag 4.1 myeloma cell.

5 The fused spleen/myeloma cells are cultured in a selective medium to select fused spleen/myeloma cells from the parental cells. Fused cells are separated from the mixture of non-fused parental cells, for example, by the addition of agents that block the *de novo* synthesis
10 of nucleotides in the tissue culture media. Exemplary and preferred agents are aminopterin, methotrexate, and azaserine. Aminopterin and methotrexate block *de novo* synthesis of both purines and pyrimidines, whereas azaserine blocks only purine synthesis. Where
15 aminopterin or methotrexate is used, the media is supplemented with hypoxanthine and thymidine as a source of nucleotides. Where azaserine is used, the media is supplemented with hypoxanthine.

20 This culturing provides a population of hybridomas from which specific hybridomas are selected. Typically, selection of hybridomas is performed by culturing the cells by single-clone dilution in microtiter plates, followed by testing the individual clonal supernatants
25 for reactivity with an antigen-polypeptide. The selected clones can then be propagated indefinitely to provide the monoclonal antibody.

 By way of specific example, to produce an antibody
30 of the present invention, mice are injected intraperitoneally with about 1-200 μ g of an antigen comprising a polypeptide of the present invention. B lymphocyte cells are stimulated to grow by injecting the antigen in association with an adjuvant such as complete
35 Freund's adjuvant (a non-specific stimulator of the immune response containing killed *Mycobacterium tuberculosis*). At some time (e.g., at least two weeks)

- 39 -

after the first injection, mice are boosted by injection with a second dose of the antigen mixed with incomplete Freund's adjuvant.

5 A few weeks after the second injection, mice are
: tail bled and the sera titered by immunoprecipitation
: against radiolabeled antigen. Preferably, the process of
: boosting and titering is repeated until a suitable titer
10 titer is achieved. The spleen of the mouse with the highest
by homogenizing the spleen with a syringe. Typically, a
spleen from an immunized mouse contains approximately 5×10^7 to 2×10^8 lymphocytes.

15 Mutant lymphocyte cells known as myeloma cells are
obtained from laboratory animals in which such cells have
been induced to grow by a variety of well-known methods.
Myeloma cells lack the salvage pathway of nucleotide
biosynthesis. Because myeloma cells are tumor cells,
20 they can be propagated indefinitely in tissue culture,
and are thus denominated immortal. Numerous cultured
cell lines of myeloma cells from mice and rats, such as
murine NS-1 myeloma cells, have been established.
Myeloma cells are combined under conditions appropriate
25 to foster fusion with the normal antibody-producing cells
from the spleen of the mouse or rat injected with the
antigen/polypeptide of the present invention. Fusion
conditions include, for example, the presence of
polyethylene glycol. The resulting fused cells are
30 hybridoma cells. Like myeloma cells, hybridoma cells
grow indefinitely in culture.

Hybridoma cells are separated from unfused myeloma
cells by culturing in selection medium such as HAT media
35 (hypoxanthine, aminopterin, thymidine). Unfused myeloma
cells lack the enzymes necessary to synthesize
nucleotides from the salvage pathway and are killed in

- 40 -

the presence of aminopterin, methotrexate, or azaserine. Unfused lymphocytes also do not continue to grow in tissue culture. Thus, only cells that have successfully fused (hybridoma cells) can grow in the selection media.

5

Each of the surviving hybridoma cells produces a single antibody. These cells are then screened for the production of the specific antibody immunoreactive with an antigen/polypeptide of the present invention. Single
10 cell hybridomas are isolated by limiting dilutions of the hybridomas. The hybridomas are serially diluted many times and, after the dilutions are allowed to grow, the supernatant is tested for the presence of the monoclonal antibody. The clones producing that antibody are then
15 cultured in large amounts to produce an antibody of the present invention in convenient quantity.

By use of a monoclonal antibody of the present invention, specific polypeptides of the invention can be
20 recognized as antigens, and thus identified. Once identified, those polypeptides can be isolated and purified by techniques such as antibody-affinity chromatography. In antibody-affinity chromatography, a monoclonal antibody is bound to a solid substrate and
25 exposed to a solution containing the desired polypeptide. The polypeptide-antigen is removed from the solution through an immunospecific reaction with the bound antibody. The polypeptide is then easily removed from the substrate and purified.

30

It is proposed that the monoclonal antibodies of the present invention will find useful application in standard immunochemical procedures, such as ELISA and Western blot methods, as well as other procedures which
35 may utilize antibody specific to bile acid transporter epitopes. Additionally, it is proposed that monoclonal antibodies specific to the particular bile acid

- 41 -

transporter may be utilized in other useful applications. For example, their use in immunoabsorbent protocols may be useful in purifying native or recombinant bile acid transporters from various species or variants thereof. A particularly useful application of such antibodies is in purifying native or recombinant bile acid transporters, for example, using an antibody affinity column. Such antibodies would also be useful as immunohistochemical or immunoblotting reagents in the diagnosis of chronic idiopathic diarrhea associated with bile acid malabsorption, ileal disease and bile acid related kidney disease. The operation of all such immunological techniques will be known to those of skill in the art in light of the present disclosure.

15.

Renal Bile Acid Cotransporter

Using the materials and methods of the present invention, the major bile acid transporter present in the kidney is shown to be identical to the ileal bile acid transporter. Based on these studies, the same complementary DNA clone can be used to develop inhibitors of the renal bile acid reabsorption, to identify renal bile acid cotransporters from other species, and other utilities analogous to those described herein for the ileal transporter. Therefore, all such uses of the renal bile acid transporter are included within the scope and spirit of the present claimed invention.

30 Nucleic Acid Hybridization

The DNA sequences disclosed herein will find utility as probes or primers in nucleic acid hybridization embodiments. As such, it is contemplated that oligonucleotide fragments corresponding to the sequences of SEQ ID NO:1 for stretches of between about 17 nucleotides to about 20, 25 or 30 nucleotides will find

- 42 -

particular utility, with even longer sequences, e.g., 40, 50, 100, even up to full length, being more preferred for certain embodiments. The ability of such nucleic acid probes to specifically hybridize to bile acid

5 cotransporter-encoding sequences will enable them to be of use in a variety of embodiments. For example, the probes can be used in a variety of assays for detecting the presence of complementary sequences in a given

10 sample. However, other uses are envisioned, including the use of the sequence information for the preparation of mutant species primers, or primers for use in preparing other genetic constructions.

Nucleic acid molecules having stretches of 10, 20, 15 30, 50, or even of 100 nucleotides or so, complementary to SEQ ID NO:1 or SEQ ID NO:3 will also have utility as hybridization probes. These probes will be useful in a variety of hybridization embodiments, such as Southern and Northern blotting in connection with analyzing

20 transporter structural or regulatory genes in diverse tissues and in various species. The total size of the fragment, as well as the size of the complementary stretches, will ultimately depend on the intended use or application of the particular nucleic acid segment.

25 Smaller fragments will generally find use in hybridization embodiments, wherein the length of the complementary region may be varied, such as between about 17 and about 100 nucleotides, or even up to 2263

30 according to the complementary sequences one wishes to detect.

The use of a hybridization probe of about 17 nucleotides in length allows the formation of a duplex molecule that is both stable and selective. Molecules

35 having complementary sequences over stretches greater than 17 bases in length are generally preferred, though, in order to increase stability and selectivity of the

- 43 -

hybrid, and thereby improve the quality and degree of specific hybrid molecules obtained. One will generally prefer to design nucleic acid molecules having gene-complementary stretches of about 20 nucleotides, or even longer where desired. Such fragments may be readily prepared by, for example, directly synthesizing the fragment by chemical means, by application of nucleic acid reproduction technology, such as the PCR technology of U.S. Patent 4,603,102 (incorporated herein by reference) or by introducing selected sequences into recombinant vectors for recombinant production.

Accordingly, the nucleotide sequences of the invention may be used for their ability to selectively form duplex molecules with complementary stretches of bile acid transporter genes or cDNAs. Depending on the application envisioned, one will desire to employ varying conditions of hybridization to achieve varying degrees of selectivity of probe towards target sequence. For applications requiring high selectivity, one will typically desire to employ relatively stringent conditions to form the hybrids, e.g., one will select relatively low salt and/or high temperature conditions, such as provided by 0.02M-0.15M NaCl at temperatures of 50°C to 70°C. Such selective conditions tolerate little, if any, mismatch between the probe and the template or target strand, and would be particularly suitable for isolating the hamster ileal and renal bile acid cotransporter genes.

30

Preferred hybridization conditions and temperatures include a solution containing 50% (volume/volume) formamide, 5X Denhardt's solution, 6X SSC, 0.1% (weight/volume) SDS, and 100 µg/ml salmon sperm DNA, and 1 mM sodium pyrophosphate at 37°C. For nucleotide sequences longer than 50 nucleotides, preferred wash conditions include a solution containing 2X SSC/0.5% SDS

35

- 44 -

at 25°C for 30 min followed by one or more washes in a solution containing 0.2X SSC/0.5% SDS at 60°C for 30 min per wash. For nucleotide sequences shorter than 50 nucleotides, preferred wash conditions include a solution
5 containing 2X SSC/1% SDS at 25°C for 30 min followed by one or more washes in a solution containing 2X SSC/1% SDS at 50°C for 30 min.

Of course, for some applications, for example, where
10 one desires to prepare mutants employing a mutant primer strand hybridized to an underlying template or where one seeks to isolate bile acid cotransporter-encoding sequences from related species, functional equivalents, or the like, less stringent hybridization conditions will
15 typically be needed in order to allow formation of the heteroduplex. In these circumstances, one may desire to employ conditions such as 0.15M-0.9M salt, at temperatures ranging from 20°C to 55°C. Cross-
hybridizing species can thereby be readily identified as
20 positively hybridizing signals with respect to control hybridizations. In any case, it is generally appreciated that conditions can be rendered more stringent by the addition of increasing amounts of formamide, which serves to destabilize the hybrid duplex in the same manner as
25 increased temperature. Thus, hybridization conditions can be readily manipulated, and thus will generally be a method of choice depending on the desired results.

In certain embodiments, it will be advantageous to
30 employ nucleic acid sequences of the present invention in combination with an appropriate means, such as a label, for determining hybridization. A wide variety of appropriate indicator means are known in the art, including fluorescent, radioactive, enzymatic or other
35 ligands, such as avidin/biotin, which are capable of giving a detectable signal. In preferred embodiments, one will likely desire to employ a fluorescent label or

- 45 -

an enzyme tag, such as urease, alkaline phosphatase or peroxidase, instead of radioactive or other environmentally undesirable reagents. In the case of enzyme tags, colorimetric indicator substrates are known which can be employed to provide a means visible to the human eye or spectrophotometrically, to identify specific hybridization with complementary nucleic acid-containing samples.

In general, it is envisioned that the hybridization probes described herein will be useful both as reagents in solution hybridization as well as in embodiments employing a solid phase. In embodiments involving a solid phase, the test DNA (or RNA) is adsorbed or otherwise affixed to a selected matrix or surface. This fixed, single-stranded nucleic acid is then subjected to specific hybridization with selected probes under desired conditions. The selected conditions will depend on the circumstances based on the particular criteria required (depending, for example, on the G+C contents, type of target nucleic acid, source of nucleic acid, size of hybridization probe, etc.). Following washing of the hybridized surface to remove nonspecifically bound probe molecules, specific hybridization is detected, or even quantified, by means of the label.

Longer DNA segments will often find particular utility in the recombinant production of peptides or proteins. DNA segments which encode peptide antigens from about 15 to about 50 amino acids in length, or more preferably, from about 15 to about 30 amino acids in length are contemplated to be particularly useful, as are DNA segments encoding entire bile acid transporter proteins. DNA segments encoding peptides will generally have a minimum coding length on the order of about 45 to about 150, or to about 90 nucleotides. DNA segments encoding full length proteins may have a minimum coding

- 46 -

length on the order of about 1,044 nucleotides for a protein in accordance with SEQ ID NO:2 or SEQ ID NO:4.

5 The nucleic acid segments of the present invention, regardless of the length of the coding sequence itself, may be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall
10 length may vary considerably. It is contemplated that a nucleic acid fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol. For example, nucleic acid
15 fragments may be prepared in accordance with the present invention which are up to 10,000 base pairs in length, with segments of 5,000 or 3,000 being preferred and segments of about 1,000 base pairs in length being particularly preferred.

20

It will be understood that this invention is not limited to the particular nucleic acid and amino acid sequences of SEQ ID NO:1- SEQ ID NO:11. Therefore, DNA segments prepared in accordance with the present
25 invention may also encode biologically functional equivalent proteins or peptides which have variant amino acids sequences. Such sequences may arise as a consequence of codon redundancy and functional equivalency which are known to occur naturally within
30 nucleic acid sequences and the proteins thus encoded. Alternatively, functionally equivalent proteins or peptides may be created via the application of recombinant DNA technology, in which changes in the protein structure may be engineered, based on
35 considerations of the properties of the amino acids being exchanged.

- 47 -

DNA segments encoding a bile acid transporter gene may be introduced into recombinant host cells and employed for expressing a bile acid transporter protein. Alternatively, through the application of genetic engineering techniques, subportions or derivatives of selected transporter genes may be employed. Equally, through the application of site-directed mutagenesis techniques, one may re-engineer DNA segments of the present invention to alter the coding sequence, e.g., to introduce improvements to the antigenicity of the protein or to test for binding site mutants in order to examine transport activity at the molecular level. Where desired, one may also prepare fusion peptides, e.g., where the transporter coding regions are aligned within the same expression unit with other proteins or peptides having desired functions, such as for immunodetection purposes.

An important use of the nucleic acid segments will be in the study of ileal disease. The nucleic acid segments of the present invention may be adapted for use in for example, *in situ* hybridization, RNA blotting, and DNA blotting for diagnostic purposes in ileal disease. In particular, diseases related to mutations in the ileal and renal bile acid cotransporters will be detectable by the use of the nucleic acid segments of the present invention.

This application of the nucleic acid segments of the present invention will also be useful in genetic screening and counseling. Congenital defects in the ileal/renal bile acid transporter are rare, but life-threatening if not recognized early. The cloned ileal/renal bile acid transporter can be used to identify a variety of genetically-linked DNA sequence variations (polymorphisms) for the ileal/renal bile acid transporter gene. In cases where a family history of bile acid

- 46 -

malabsorption is suspected, the nucleic acid segments of the present invention can be used for prenatal or neonatal diagnosis.

5 In a further embodiment, the nucleic acid sequences of the present invention may be used to synthesize anti-sense or ribozyme probes to down-regulate expression of the bile acid transporter in the ileum for use as plasma cholesterol-lowering agents. For example, an anti-sense
10 probe that is designed to hybridize to the mRNA synthesized from the bile acid cotransporter gene would, when introduced into the ileal cells, disrupt translation of the mRNA and would hence lower the expression of the cotransporter. The lowered levels of cotransporter would
15 function to lower plasma cholesterol levels. A similar embodiment would be possible in the kidney cells for use as plasma bile acid-lowering agents in the treatment of cholestasis, jaundice, liver cirrhosis, primary biliary cirrhosis, and sclerosing cholangitis.

20

Screening Assays

 In still further embodiments, the present invention concerns a method for identifying new bile acid transport
25 inhibitory compounds, which may be termed as "candidate substances." It is contemplated that this screening technique will prove useful in the general identification of any compound that will serve the purpose of inhibiting ileal and/or renal bile acid transport. It is further
30 contemplated that useful compounds in this regard will in no way be limited to bile acid analogues. In fact, it may prove to be the case that the most useful pharmacological compounds for identification through
application of the screening assay will serve to
35 inactivate the transport through a tight binding or other chemical interaction.

- 49 -

Accordingly, in screening assays to identify pharmaceutical agents which affect bile acid transport, it is proposed that compounds isolated from natural sources such as synthetic bile acid derivatives, fungal extracts, plant extracts, bacterial extracts, higher eukaryotic cell extracts, or even extracts from animal sources, or marine, forest or soil samples, may be assayed for the presence of potentially useful pharmaceutical agents. It will be understood that the pharmaceutical agents to be screened could also be derived from chemical compositions or man-made compounds other than synthetic bile acid derivatives. In important aspects, the candidate substances may be anti-bile acid transporter antibodies, including polyclonal and monoclonal antibodies. The suspected agents could also include proteins and peptides, such as those derived from recombinant DNA technology or by other means, including peptide synthesis. The active compounds may include fragments or parts of naturally-occurring compounds or may be only found as active combinations of known compounds which are otherwise inactive.

To identify a candidate substance capable of inhibiting bile acid transport, one would first obtain a recombinant cell line capable of expressing ileal/renal bile acid transport. Naturally, one would measure or determine the activity of the bile acid transport in the absence of the added candidate substance. One would then add the candidate substance to the cell growth media or expose the cells in an appropriate way to the candidate substance and re-determine the ability of the cells to transport bile acid in the presence of the candidate substance. A candidate substance which reduces the activity of the bile acid transporter relative to the activity in its absence is indicative of a candidate substance with inhibitory capability. The indicator in the screening assays will preferably be taurocholate and

- 50 -

more preferably tritium labeled taurocholate. For an example of a taurocholate uptake assay, see Example 3, *infra*.

5 In the most preferred embodiment, stably transfected ileal/renal bile acid transporter over-expressing cell lines will be used for high throughput assays to screen synthetic bile acid derivatives, fungal extracts, plant
10 extracts, bacterial extracts, higher eukaryotic cell extracts or others as mentioned above, for potential inhibitors of the bile acid transporter for use as plasma cholesterol-lowering agents. In addition, these various
15 extracts will be screened for use in the treatment of disorders such as cholestasis, jaundice, primary biliary cirrhosis, sclerosing cholangitis and others.

Promoter/Reporter Gene Fusions

20 The present invention also provides candidate substance screening methods which are based upon whole cell assays and which, preferably, employ a reporter gene that confers on its recombinant hosts a readily detectable phenotype to indicate expression from the cotransporter gene promoter. Generally, reporter genes
25 encode a polypeptide not otherwise produced by the host cell which is detectable by analysis of the cell culture, e.g., by fluorometric, radioisotopic or spectrophotometric analysis of the cell culture. Exemplary enzymes include esterases, phosphatases,
30 proteases (tissue plasminogen activator or urokinase) and other enzymes capable of being detected by their activity, as will be known to those skilled in the art. A preferred example is *E. coli* beta-galactosidase, which produces a color change upon cleavage of an indigogenic
35 substrate. Another preferred example is the enzyme chloramphenicol acetyltransferase (CAT) in which activity is preferably determined by detection of a radioactively

- 51 -

labelled substrate by scintillation counting or by thin layer chromatography followed by autoradiography. A more preferred example is the enzyme luciferase in which activity is preferably determined by detection of light using a luminometer.

Another class of reporter genes which confer detectable characteristics on a host cell are those which encode polypeptides, generally enzymes, which render their transformants resistant against toxins, e.g., the neo gene which protects host cells against toxic levels of the antibiotic G418; or a gene encoding dihydrofolate reductase, which confers resistance to methotrexate. Genes of this class are not generally preferred since the phenotype (resistance) does not provide a convenient or rapid quantitative output. Resistance to antibiotic or toxin requires days of culture to confirm, or complex assay procedures if other than a biological determination is to be made.

Other genes for use in the screening assay herein are those capable of transforming hosts to express unique cell surface antigens, e.g., viral env proteins such as HIV gp120 or herpes gD, which are readily detectable by immunoassays. However, antigenic reporters are not preferred because, unlike enzymes, they are not catalytic and thus do not amplify their signals.

The polypeptide products of the reporter gene are secreted, intracellular or, as noted above, membrane bound polypeptides. If the polypeptide is not ordinarily secreted it is fused to a heterologous signal sequence for processing and secretion. In other circumstances the signal is modified in order to remove sequences that interdict secretion. Preferably, however, the products of the reporter gene are lodged in the intracellular or membrane compartments. Then they can be fixed to the

- 52 -

culture container, e.g., microtiter wells, in which they are grown, followed by addition of a detectable signal generating substance such as a chromogenic substrate for reporter enzymes.

5

In general, the sequences of the present invention are employed to control transcription and expression of the reporter gene. The process which in its entirety leads to enhanced transcriptional promotion is termed "activation." Alternatively, the process which in its entirety leads to reduced transcriptional promotion is termed "inhibition." The mechanism by which a successful candidate substance acts is not material since the objective is to promote or repress gene expression, and particularly, to activate or inhibit the ileal/renal bile acid transporter gene, by whatever means will function to do so.

The promoter, whether a hybrid or the native bile acid cotransporter promoter, is ligated to DNA encoding the reporter gene by conventional methods. The bile acid cotransporter promoter is obtained by *in vitro* synthesis or recovered from genomic DNA. It is ligated upstream of the start codon of the reporter gene. The promoter also will contain an AT-rich region (TATA box), located between the bile acid cotransporter promoter and the reporter gene start codon. The region 3' to the coding sequence for the reporter gene will contain a transcription termination and polyadenylation site, for example the hepatitis B polyA site. The promoter and reporter gene are inserted into a replicable vector and transfected into a cloning host such as *E. coli*. The host is then cultured and the replicated vector is recovered in order to prepare sufficient quantities of the construction for later transfection into a suitable eukaryotic host.

- 53 -

The host cells used in the screening assay herein generally are mammalian cells, and are preferably cell lines which may be used in connection with stable and/or transient transfection assays. It is also important for inhibitor screening, that the cell line be one in which the gene is constitutively expressed so that inhibition can be measured. Cell lines should be relatively easy to grow in large scale culture. Also, they should contain as little native background as possible considering the nature of the reporter polypeptide. Examples include the Hep G2, VERO, HeLa, CHO, W138, BHK, COS-7, and MDCK cell lines, with CHO cells being preferred. Since the ileal/renal bile acid transporter is selectively expressed in the ileum and kidney, cells of intestinal and renal origin are more preferred. Examples include CaCo₂ cells and OK cells. The vector is cotransfected into the desired host, stable transformants selected and, optionally, the reporter gene and its controlling promoter are amplified in order to increase the screening assay sensitivity. This is accomplished in conventional fashion by cotransforming the host with the reporter gene and a selectable marker gene such as DHFR (for DHFR minus host cells such as CHO) or DHFR and neo for other hosts, followed by the application of a selection agent.

The screening assay typically is conducted by growing the transformants to confluency in microtiter wells, adding 5 to 50 μ M [³H]taurocholate with 0.1 to 100-fold serial molar proportions of candidate therapeutic agents to a series of wells. The signal level is determined after an incubation period that is sufficient to demonstrate expression in controls incubated solely with 5 to 50 μ M [³H]taurocholate. The wells containing varying proportions of candidate are then evaluated for signal activation. Candidates that demonstrate dose related enhancement/repression of reporter gene transcription or expression are then

- 54 -

selected for further evaluation as clinical therapeutic agents.

5 Candidate substances that are found to inhibit the
expression of the ileal bile acid transporter gene
expression in the ileum will be useful as plasma
cholesterol-lowering agents and those that inhibit the
renal bile acid transporter gene expression in the kidney
10 will be useful for the treatment of cholestasis,
jaundice, primary biliary cirrhosis, and sclerosing
cholangitis. Candidate substances that are found to
activate the expression of the ileal bile acid
transporter gene expression in the ileum will have use in
15 patients with ileal disease or Crohn's disease and in
patients who have undergone ileal resection.

It should be understood that the screening method
herein is useful notwithstanding that effective
candidates may not be found, since it would be a
20 practical utility to know that bile acid cotransporter
activators and/or inhibitors do not exist. The invention
consists of providing a method for screening for such
candidates, not in finding them.

25 Gene Therapy

The ileal/renal bile acid transporter encoding
nucleic acids will also be useful for gene therapy to
restore bile acid uptake activity to patients whose ileum
30 has been surgically resected for diseases like Crohn's
disease, patients who were born with congenital defects
in the bile acid transporter, and patients who suffer
from adult-onset chronic idiopathic bile acid diarrhea.

35 For example, the use of recombinant viruses
engineered to express mammalian ileal/renal bile acid
cotransporter is also envisioned. A variety of viral

- 55 -

vectors, such as retroviral vectors, herpes simplex virus (U.S. Patent 5,288,641, incorporated herein by reference), cytomegalovirus, and the like may be employed, as described by Miller (1992, incorporated herein by reference). Recombinant adeno-associated virus (AAV) and AAV vectors may also be employed, such as those described in U.S. Patent 5,139,941, incorporated herein by reference. Recombinant adenoviral vectors are currently preferred. Techniques for preparing replication-defective infective viruses are well known in the art, as exemplified by Ghosh-Choudhury & Graham (1987); McGrory et al. (1988); and Gluzman et al. (1982), each incorporated herein by reference. One advantage to this type of therapy is that cotransporter expression is believed to be tissue specific and therefore expression in other tissue types would not be expected to be a problem as in viral/toxin therapy.

Another method of gene therapy may involve lysosomal carriers of the nucleic acid. In either case, the nucleic acid is conjugated to a cationic carrier such as poly-L-lysine for delivery to target cells.

The characterization of the ileal Na⁺-dependent bile acid cotransporter will have utility in a wide range of human and veterinary clinical applications as disclosed above. In addition to the clinical applications, understanding the mechanism and regulation of intestinal and renal bile acid transport will yield new and useful information directly related to the role of bile acids in lipid absorption, cholesterol homeostasis, and the pathogenesis and treatment of hypercholesterolemia and gastroenterological disease.

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the

- 56 -

techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

EXAMPLE I

CLONING OF THE ILEAL BILE ACID TRANSPORTER

Materials and Methods

Certain standard molecular biology techniques were employed in the present study (Sambrook et al., 1989). Total cellular RNA was isolated by the guanidinium thiocyanate/CsCl centrifugation procedure (Chirgwin et al., 1979). Poly(A)⁺ RNA was isolated using oligo(dT)-cellulose spin columns from Pharmacia LKB Biotechnology Inc. For Northern blot analysis, poly(A)⁺ RNA was fractionated on 1.2% agarose gels containing 2.2 M formaldehyde, transferred to GeneScreen (Dupont-NEN) and hybridized with single-stranded ³²P-labeled M13 DNA probes (Church & Gilbert, 1984). Restriction fragments derived from the IBAT cDNA were inserted into M13 and pBluescript KS II (Stratagene) vectors and sequenced on both strands by the dideoxy chain termination method using the M13 universal sequencing primer or pBluescript-specific primers (Sambrook et al., 1989).

Construction of pCMV-Liver Bile Acid Transporter Plasmid

The polymerase chain reaction (Saiki et al., 1988) was used to obtain a rat liver Na⁺/bile acid cotransporter (LBAT) cDNA. This clone was used as a

- 57 -

positive control to optimize the bile acid transporter expression screening strategy. To obtain a liver bile acid transporter clone, first strand cDNA was synthesized from rat liver poly(A)⁺ RNA. For the PCR, oligonucleotide primers corresponding to nucleotides 113-133 and 1193-1216, which flanked the amino- and carboxyl-terminal sequences of the rat LBAT, were used (Hagenbuch et al., 1991). Following amplification, a product of the appropriate size (1104 base pairs) was excised from a 0.8% (w/v) agarose gel, and isolated by electroelution. The PCR product was treated with T4 DNA polymerase, phosphorylated with T4 polynucleotide kinase, and ligated into *Sma* I-cut pCMV₂ (Anderson et al., 1989). The authenticity of the bile acid transporter insert was verified by dideoxy sequencing.

Construction of cDNA Expression Library

Male golden Syrian hamsters (90-150 g) were purchased from Sasco (Omaha, NE) and maintained on a normal chow diet (ground Wayne Lab Blox 8604; Allied Mills, Chicago, IL) and a 12-h light/12-h dark cycle for at least 10 days prior to use.

Hamster ileal poly(A)⁺ RNA was used to construct a size-selected cDNA library with a kit purchased from Invitrogen (catalog number L0804-15). Poly(A)⁺ RNA (5 µg) was denatured with methylmercury hydroxide at room temperature prior to first strand synthesis. Double-stranded oligo(dT)-primed cDNA was synthesized and ligated to *Bst* XI adapters according to the manufacturer's protocol. cDNAs greater than 2200 base pairs in length were excised from a 0.8% (w/v) agarose gel, isolated by electroelution, and then ligated into the *Bst* XI sites of the plasmid expression vector pCMX (Davis et al., 1991). The library was titered by electroporation into *E. coli* HB101 cells and contained

- 58 -

approximately 1.2×10^7 independent recombinants. Aliquots of the library were electroporated into *E. coli* HB101 cells, spread onto LB plates containing 50 $\mu\text{g/ml}$ ampicillin, and grown for 12 hours at 37°C. Pools of colonies (approximately 3×10^3 independent cDNAs per pool) were scraped from the plates, grown for 4 hours in 25-ml cultures of SOC medium with ampicillin, and plasmid DNA was purified using Qiagen-tip 20 columns (Qiagen Inc., Chatsworth, CA).

Expression Cloning of Ileal Bile Acid Transporter

Pools of cDNA clones were transfected into COS cells, and subsequently analyzed for uptake of [^3H]taurocholate in a transient assay. On day 0, dishes of 5×10^5 cells per 60-mm dish were plated in medium A. On day 1, duplicate dishes of cells were each transfected with 2 μg of the library plasmid pool by the DEAE-dextran method (Esser et al., 1988). On day 4, the cells were incubated with medium B supplemented with 5 μM [^3H]taurocholate (2.0-2.6 Ci/mmol). After incubation for 1 hour at 37°C, the medium was removed, and each cell monolayer was washed 5 times with ice-cold PBS plus 0.2% (w/v) BSA and 1 mM taurocholate, then once with ice-cold PBS alone. The cell monolayer was then dissolved in 0.1 N NaOH and aliquots were taken to determine cell-associated protein and radioactivity. Seven library plasmid pools that expressed [^3H]taurocholate uptake activity were identified, and one pool was progressively subdivided into smaller pools (sib selection) until a single positive clone was obtained.

Two control assays were routinely performed for each transfection study. As a negative control, COS cells were transfected with 2 μg of pCMV- β -galactosidase (pCMV- β gal; Briggs et al., 1993). As a positive control, COS

- 59 -

cells were transfected with 2 ng of pCMV-LBAT plus 2 μ g of pCMV- β gal.

Results

5
Starting with the size-fractionated hamster ileal cDNA expression library, plasmid DNA was prepared from cultures of 1000-5000 independent bacterial transformants and introduced into COS-1 cells using a DEAE-dextran
10 transfection procedure. The transfected cells were then assayed for [3 H]taurocholate uptake activity. COS-1 cells were selected for the expression assays since preliminary studies indicated that mock or pCMV-gal transfected COS cells lack a Na $^+$ -dependent taurocholate
15 uptake activity. A total of 202 pools representing approximately 650,000 clones were screened yielding 7 pools which exhibited bile acid uptake activity two to six-fold greater than the pCMV- β gal transfected COS
cells. FIG. 1A summarizes the hamster ileal library
20 screening.

From positive pool 41-1, 18 pools of approximately 500 clones each were prepared and one subpool (41-1/S7) was found to be positive in the taurocholate uptake
25 assay. This pool was further subfractionated into 48 pools of approximately 50 clones each, and 6 of these subpools exhibited significant taurocholate uptake activity. Two hundred individual clones from plasmid subpool 41-1/S7/S15 were then plated onto two 10 X 10
30 matrices and plasmid pools corresponding to each row and column were prepared. Two rows and two columns were found to exhibit significant taurocholate uptake activity. The four clones at the intersection of the
positive rows and columns were then assayed individually,
35 and two of the clones were determined to be positive. The two positive clones were identical by restriction digest analysis and one clone (C13/R13) was designated

- 60 -

pIBAT (ileal Na⁺/bile acid cotransporter) and used for further study. Transfection of the C13/R13 cDNA clone into COS cells stimulated [³H]taurocholate uptake almost 1000-fold (FIG. 1B).

5

Using the polymerase chain reaction with pIBAT-specific oligonucleotides, the 6 remaining pools from the original expression cloning screen were examined and determined to contain IBAT cDNA clones. To isolate the additional clones, pIBAT was used to screen the 6 positive pools by colony hybridization. Mapping and partial sequencing of the 4 longest clones revealed different lengths for the 5'- and 3'- untranslated regions, but no apparent differences in the predicted coding sequence.

10

15

EXAMPLE II

SEQUENCE ANALYSIS OF THE ILEAL BILE ACID TRANSPORTER

Methods

20

Sequences were analyzed using programs obtained from the Genetics Computer Group Sequence Analysis Software Package, Version 7.1 (Devereux et al., 1984).

25

Results

The IBAT DNA sequence was determined and the corresponding amino acid sequence deduced. The hamster IBAT cDNA encodes a protein of 348 amino acids (SEQ ID NO:2) with a calculated molecular mass of 37,894 Da. The predicted initiator methionine lies within an appropriate consensus for initiation of translation (Kozak, 1987) and is preceded by a 5'-untranslated region of 108 nucleotides which contains an in-frame stop codon. The translation termination codon is followed by a 3'-untranslated region of 1108 nucleotides which did not extend to the poly(A) tail.

30

35

- 61 -

A search of available protein and nucleic acid databases revealed that the hamster IBAT protein sequence was 35% identical and 63% similar to the rat LBAT (Hagenbuch et al., 1991). In addition, the two proteins share similar hydropathy profiles, suggesting that both proteins assume the same topology in the plasma membrane (FIG. 2). Both cDNAs are predicted to encode a protein that lacks a cleavable signal sequence (von Heijne, 1983) and contains 7 or 8 potential transmembrane domains. The hamster IBAT also has three potential N-linked glycosylation sites.

EXAMPLE III

FUNCTIONAL CHARACTERIZATION OF THE ILEAL BILE ACID TRANSPORTER

Methods

Cell Culture

[³H]taurocholic acid (2.0-2.6 Ci/mmol) was obtained from Du Pont-New England Nuclear. Unlabeled bile acids were purchased from the Sigma Chemical Co. (St. Louis, Mo) and CalBiochem (San Diego, CA). COS-1 cells were obtained from American Type Culture Collection. RNA molecular weight standards were obtained from Gibco-BRL, (Grand Island, NY).

All cells were grown in monolayer at 37°C in an atmosphere of 5% CO₂. COS cells were maintained in medium A which consisted of Dulbecco's modified Eagle's minimum essential medium containing 4500 mg/L D-glucose, 10% (v/v) fetal calf serum, 100 units/ml penicillin, and 100 µg/ml streptomycin (Gibco, Inc., Grand Island, NY). For bile acid uptake assays, COS cells were switched to medium B which consisted of Dulbecco's modified Eagle's minimum essential medium containing 4500 mg/L D-glucose, 0.2% (w/v) fatty acid-free BSA (Sigma), 100 units/ml

- 62 -

penicillin, and 100 μ g/ml streptomycin. To analyze the Na^+ -dependence of bile acid uptake, COS cells were switched to medium C which contained a modified Hank's balanced salt solution (Chandler et al., 1993), 0.2% (w/v) fatty acid-free BSA (Sigma), 100 units/ml penicillin, and 100 μ g/ml streptomycin.

Taurocholate Uptake Assays

A modified [^3H]taurocholate uptake assay was used to characterize the IBAT cDNA clone. On day 0, dishes of 1.50×10^6 cells per 100-mm dish were plated in medium A. On day 1, the cells were transfected by the DEAE-dextran method (Esser et al., 1988) with 5 μ g plasmid DNA. On day 2, the transfected cells were trypsinized, pooled, and replated in 24 well culture plates at 7×10^4 cells/well. On day 4, the cells were incubated with medium B or C supplemented with the indicated concentration of [^3H]taurocholate. After the indicated amount of time at 37°C, the medium was removed, and each cell monolayer was washed and processed to determine cell-associated protein and radioactivity as described above.

Results

Na^+ -dependent bile acid uptake has been demonstrated in brush border membranes of the kidney (Wilson et al., 1981) and the sinusoidal membranes of the liver (Boyer et al., 1992). In the small intestine, active bile acid transport has been characterized in the ileum but is notably absent from the duodenum and proximal jejunum (Wilson, 1981). To compare IBAT mRNA expression with the known tissue distribution of bile acid transport activity, Northern blot analysis was performed with poly(A) $^+$ RNA from hamster kidney, liver, duodenum, jejunum, and ileum.

- 63 -

It was found that a single message of approximately 4.0 kb was readily detected in hamster ileum and kidney and weakly detectable in hamster jejunum (FIG. 3). No hybridization was observed with mRNA from hamster liver or duodenum, even after prolonged exposure of the blots. Stripping and reprobing the blots with a probe for glyceraldehyde-3-phosphate dehydrogenase (GAPD) (Ercolani et al., 1988) confirmed that equal amounts of RNA were loaded in each lane (FIG. 3, lower panel).

10

A critical property of the ileal bile acid transporter is its dependence on an external Na^+ gradient (Lack, 1979). To examine IBAT's Na^+ -dependence, pIBAT-transfected COS cells were incubated in a modified Hanks buffer containing either 137 mM Na^+ or equal concentrations of tetraethylammonium (TEA), K^+ , or choline. It was found that small cations such as K^+ or organic cations such as TEA and choline were unable to support $[^3\text{H}]$ taurocholate uptake (FIG. 4). However, in the presence of Na^+ , $[^3\text{H}]$ taurocholate was stimulated over 100-fold.

20

To examine the kinetics of bile acid uptake by IBAT, transfected COS cells were incubated for 15 minutes with increasing concentrations of $[^3\text{H}]$ taurocholate. Preliminary studies have shown that transport of 5 μM $[^3\text{H}]$ taurocholate was linear with time for 30 minutes at 37°C. Transport of $[^3\text{H}]$ taurocholate by the pIBAT-transfected COS cells exhibited saturable kinetics (FIG. 5A). As determined by Eadie-Hofstee analysis, IBAT exhibited taurocholate uptake activity with an apparent K_m of 33 μM and a V_{max} of 396 $\text{pmol min}^{-1} \text{mg}^{-1} \text{protein}$ (FIG. 5B).

25

30

35

To examine the transport specificity of the IBAT protein, COS cells were transfected with the IBAT cDNA and incubated with 50 μM unlabeled bile acid or other

- 64 -

competitor. At a 10-fold molar excess of unlabeled bile acid, [³H]taurocholate uptake was inhibited 87% with taurochenodeoxycholate, 80% with taurodeoxycholate, 63% with taurocholate, 61% with glycocholate, and 51% with cholate, whereas the unlabeled amino acid taurine had a limited effect (FIG. 6A). At equal concentrations, the dihydroxy bile acids (taurochenodeoxycholate and taurodeoxycholate) competed more effectively for [³H]taurocholate uptake than unlabeled taurocholate, a trihydroxy bile acid.

Cholephilic organic compounds such as bromosulfophthalein (BSP) and the bifunctional anion transport inhibitor 4,4'-diisothiocyano-2,2'-disulfonic acid stilbene (DIDS) have been shown to inhibit Na⁺-dependent taurocholate uptake by liver membranes (Zimmerli et al., 1989) but not ileal brush border membranes (Kramer et al., 1992). Uptake of [³H]taurocholate by pIBAT-transfected COS cells was determined not to be significantly inhibited by the addition of BSP or DIDS (FIG. 6B).

EXAMPLE IV

USE OF NUCLEIC ACID SEGMENTS TO ISOLATE FULL LENGTH GENOMIC SEQUENCES

The nucleic acid sequences of the present invention may be used to isolate the full length genomic sequences encoding the ileal/renal bile acid transporters and surrounding control regions. A genomic library could be constructed by well known techniques such as those taught in Sambrook et al., (1989). For example, genomic DNA may be isolated from the hamster or human ileal tissue and partially digested with a restriction enzyme such as Sau 3A. The digested DNA would then be packaged in a lambda vector by the use of the Packagene system (Promega) for example. This library could then be screened analogously

- 65 -

to the expression screening of the cDNA library described in Example I. Alternatively, the genomic clones could be transferred to a solid substrate such as a nitrocellulose filter and hybridized to labeled nucleic acid sequences of the present invention in order to select for the bile acid cotransporter genes.

It is understood that because of interspecies homology, the nucleic acid segments of the present invention will also be useful to isolate the genomic sequences or even cDNA sequences from other species of mammals. The nucleic acid segments of the present invention of any size up to and including the entire sequence designated as SEQ ID NO:1 or SEQ ID NO:3 could be labelled and used as a probe to isolate the genomic sequences, including the intron sequences and control sequences for gene expression of the ileal/renal bile acid cotransporter. An important use of this sequence information would be to determine whether the ileal and renal genes are controlled by similar promoter/enhancer elements or whether there are tissue specific differences. This would enable the targeting of activators/repressors to specific tissues. The isolation of the promoter regions will also allow the screening of candidate substances as activators or inhibitors of genetic expression of the bile acid cotransporters.

In order to identify the desired genomic sequences, the individual clones could be separated, for example by polyacrylamide gel electrophoresis, or agarose gel electrophoresis and then transferred to a filter such as a nitrocellulose filter or any other suitable material. The nucleic acid probe would then be labelled with ³²P by enzymatic labelling with polynucleotide kinase, for example. The clone could also be radioactively labelled by nick translation or in a polymerase chain reaction that included radiolabeled nucleotides. Alternatively,

- 66 -

the probe could be labelled with a fluorescent marker such as biotin or any fluorophore. Such labelling techniques are well known in the art.

5 The labelled probe would then be hybridized to the denatured DNA on the filter and washed under increasingly stringent conditions, incrementally higher temperatures for example, until the positive clones can be identified by autoradiography or by fluorescence. These positive
10 clones would then be rescreened and sequenced to determine the full gene sequence encoding the ileal/renal bile acid cotransporter protein.

 The full protein could then be expressed in an *E. coli* strain, for example, and used for further analysis. It is understood that the protein could also be truncated or altered by site directed mutagenesis, for example and that such altered proteins or partial sequences would also fall within the scope of the present invention.

20

EXAMPLE V PRODUCTION OF ANTIBODIES

 A synthetic peptide (obtained from Research
25 Genetics, San Diego, CA) corresponding to amino acids 335-348 (SEQ ID NO:5) of the hamster ileal Na⁺/bile acid cotransporter was coupled to tuberculin purified protein derivative (PPD; Statens Serum Institut, Copenhagen, Denmark) using glutaraldehyde. Three New Zealand White
30 rabbits were immunized with 500 µg of coupled peptide in Freund's complete adjuvant. Rabbit serum was assayed by immunoblot analysis for anti-ileal bile acid transporter antibody using bile acid transporter-transfected COS cell extracts as well as ileal brush border membrane. To
35 demonstrate the specificity of the antibody, 100 µg of rat jejunal or ileal brush border membrane protein was denatured and reduced in Laemmli sample buffer containing

- 67 -

2% (w/v) SDS and 2.5% (v/v) β -mercaptoethanol. The protein was then subjected to electrophoresis on a 10% SDS-polyacrylamide gel and either stained with coomassie blue (FIG. 7A) or transferred to a nitrocellulose filter (FIG. 7B). The nitrocellulose filter was incubated with 1.8 μ g/ml of rabbit antipeptide IgG directed against amino acids 335-348 (SEQ ID NO:5) of the hamster ileal bile acid transporter. To visualize the primary antibody, the filter was incubated with alkaline phosphatase-conjugated goat antirabbit IgG(1:2500 dilution; BioRad, cat no. 170-6518). The position of molecular weight markers run in adjacent lanes were determined by staining the nitrocellulose filter with ponceau S prior to blocking the filter with Blotto.

15

EXAMPLE VI

ISOLATION OF HUMAN ILEAL/RENAL BILE ACID TRANSPORTER cDNA

The polymerase chain reaction was used to derive an unambiguous probe for cDNA screens and to characterize hybridizing lambda phage clones. Oligonucleotides corresponding to amino acids 75 to 81 and 260 to 267 of the hamster ileal bile acid transporter were used in a polymerase chain reaction to derive an unambiguous probe for cDNA library screens. The polymerase chain reaction was performed with approximately 100 ng of first strand human ileal cDNA and 50 pmoles of primers. The reaction mixture was boiled, after which PCR was carried out sequentially for 1 min at 94°C, 2 min at 45°C, and 3 min at 72°C with Taq polymerase for 35 cycles. The specific 576 bp PCR product was resolved on a 1 % agarose gel, eluted from the gel slice and subcloned into the vector pT7Blue (Novagen, Madison, WI). After sequencing the PCR product in the pT7Blue vector, the PCR insert corresponding to amino acids 76 to 267 of the human ileal/renal bile acid transporter was excised from the

- 68 -

pT7Blue plasmid using Eco R1 and Hind III. The isolated insert was uniformly labeled with ^{32}P by the random-hexamer labeling procedure.

5 Plaques (1.2×10^6) from a human ileal cDNA library were screened using the ^{32}P -labeled probe derived from the polymerase chain reaction product. Filters were hybridized at 42°C in 50% formamide containing 1×10^6 cpm/ml of hybridization probe and washed in 0.2X SSC (1X
10 SSC = 150 mM sodium chloride and 15 mM sodium citrate, pH 7) and 0.5% SDS at 60°C . Seven positive clones were obtained and characterized. Two of the positive clones, designated pH60 and pH13, each of which encoded part of
15 the gene were fused to make a single clone encoding the entire gene. This clone was designated as pHIBAT and was used for subsequent studies. Phage DNA was prepared and cDNA inserts were subcloned into pBluescript KSII vectors for restriction mapping and DNA sequencing. The human
20 cDNA genetic sequence is designated herein as SEQ ID NO:3 and the derived amino acid sequence is designated SEQ ID NO:4.

EXAMPLE VII

DETECTION OF MUTANT ALLELE IN HUMAN PATIENT

25 To demonstrate the general utility of the invention, the human ileal bile acid transporter cDNA clone was used to identify a point mutation which inactivates the ileal bile acid transporter in a patient with Crohn's disease.

30 The patient, a 27 year old white female, complained of midabdominal pain, loose stools, and weight loss for one year. Results from an upper GI exam and colonoscopy revealed irregularities in the terminal ileum consistent
35 with Crohn's disease. She was referred for exploratory laparotomy and bowel resection. Following resection of the inflamed region of the terminal ileum, the resected

- 69 -

sample was sent to pathology where a biopsy was removed. The biopsy was used to construct a cDNA library in the vector lambda gt10. The library was screened using a ³²P-labeled probe derived from the human ileal/renal bile acid transporter. In this particular example, an entire cDNA clone of the human ileal bile acid transporter gene was labeled and used as the probe. Filters were hybridized at 42°C in 50% formamide containing 1x10⁶ cpm/ml of hybridization probe and washed in 0.2X SSC (1X SSC = 150 mM sodium chloride and 15 mM sodium citrate, pH 7) and 0.5% SDS at 60°C. Phage DNA from the positive clones was prepared and cDNA inserts were subcloned into pBluescript KSII vectors for restriction mapping and DNA sequencing. A single nucleotide change was detected at codon 290 of the predicted coding sequence. The C-to-T transition changed the predicted amino acid from the normal proline residue to a serine.

To assess the functional significance of such a change, the cDNA insert containing the entire coding sequence were subcloned into the expression plasmid, pCMV5 for transfection studies. As shown in FIG. 9, the normal human ileal/renal bile acid transporter was able to actively take up bile acids following transfection into COS cells, whereas the bile acid transporter with the proline to serine mutation at position 290 was completely inactive. Analysis of the ileal/renal bile acid transporter protein expressed in the transfected cells revealed that approximately equal amounts of protein were expressed. Therefore, even though the mutant ileal/renal bile acid transporter was competent for protein expression, the expressed protein was unable to transport bile acids. Additional screening of the library constructed from the patient identified 2 additional clones encoding serine at position 290, and 2 additional clones encoding proline at position 290. This suggests that the patient is heterozygous for the

- 70 -

ileal/renal bile acid transporter mutation. The probes used to discover the mutation are also useful in analyzing the inheritance of the proline to serine 290 mutation in related family members and in understanding the relationship between the mutation and the pathogenesis of Crohn's disease.

EXAMPLE VIII INHIBITION OF BILE ACID TRANSPORTER

Bile acids are synthesized from cholesterol in the liver. This process is tightly regulated to maintain the proper bile acid pool size. If the pool expands, bile acid synthesis decreases, whereas if the pool contracts, more cholesterol is converted to bile acids. Following their synthesis, bile acids are secreted into the small intestine where they act to facilitate fat absorption. Bile acids are then taken up by a specific transporter in the distal small intestine, secreted into the portal circulation, and transported into the liver for resecretion into bile. This process is extremely efficient; only about 5% of the total bile acid escapes reabsorption in the intestine and is lost in the stool. In man, this represents a major route for the elimination of cholesterol (the precursor to bile acids) and has been exploited for many years as a means of lowering plasma cholesterol levels. This approach involves the use of nondigestible charged resins which, when ingested, bind up bile acids in the small intestine and block their reabsorption. This approach requires that the patient consume substantial quantities (15-30 g/day) of the bile acid-sequestrants several times a day. Common side effects include nausea, bloating, constipation and intestinal blockage. As a result, patient compliance is poor and this therapy has met with mixed success.

- 71 -

An alternative strategy would be to directly inhibit the intestinal bile acid transporter. Several strategies are now possible with the use of the present invention. For example, naturally occurring inhibitors may be found with the screening methods disclosed herein.

Alternatively, inhibitors may be designed, based on the predicted structure of the cotransporter protein made possible by the amino acid sequences disclosed herein. Another alternative would be antisense and ribozyme technology based on the nucleic acid sequences of the present invention. For example, oligonucleotides complementary to the mRNA sequence of the cotransporter gene could be targeted to the ileal tissues to interfere with translation and thus expression of the cotransporter.

EXAMPLE IX TREATMENT OF CIRRHOSIS

In patients with liver cirrhosis, primary biliary cirrhosis, sclerosing cholangitis and other diseases which block the normal secretion of bile acids by the liver, bile acids accumulate in the liver and systemic circulation. While not a direct cause of the disease, the accumulation of bile acids is associated with the symptoms and progression of the disease. In these patients, the liver continues to degenerate, eventually leading to liver failure and death. Current treatment for this cholestasis includes the administration of a naturally-occurring, but low abundance bile acid, Ursodeoxycholic acid (UDCA). UDCA is believed to act by promoting the movement of cytotoxic bile acids from the liver into the systemic circulation. This treatment improves liver function, but does not stop the progression of the disease. As an alternative, liver transplant is an effective, but very expensive treatment. Unfortunately, even though a majority of liver

- 72 -

transplants are performed to treat these disorders, the cost of the procedure and shortage of liver donors limits its usefulness.

5 An alternative treatment strategy would be to directly inhibit the kidney bile acid transporter which reabsorbs bile acids in the renal tubules. This is predicted to increase elimination of cytotoxic bile acids from the body via the urine. The bile acid transporter's
10 sequence as disclosed herein will allow the discovery of suitable reagents to aid in the design of inhibitors. The currently available technology to screen for inhibitors is to use intact laboratory animals, or
15 laboratory animal kidney sections. However, this strategy is technically cumbersome, limited to small numbers of compounds, and expensive. The renal bile acid cotransporter may be inhibited in a similar way to the ileal bile acid cotransporter as described in Example VIII, *supra*.

20

EXAMPLE X TREATMENT OF CHRONIC DIARRHEA

Chronic diarrhea is a serious clinical problem whose
25 cause may remain elusive even after complete diagnostic examination. One possible pathophysiologic mechanism for diarrhea in these patients is malabsorption of bile acids by the ileum. It is well accepted that ileal resection or ileal disease can result in malabsorption of bile
30 acids and that unabsorbed bile acids can induce a watery diarrhea in those patients. However, the issue of the contribution of bile acid malabsorption to the pathogenesis of diarrhea has not been resolved with the currently available diagnostic tests.

35

One possibility is that the ileal bile acid transporter gene itself is defective or aberrantly down-

- 73 -

regulated in patients with chronic idiopathic diarrhea. The sequences of the present invention can be used for diagnosis through the creation of antibodies and DNA probes that target regions of mutation responsible for the disfunction. In other embodiments, gene therapy may be possible using the nucleic acid sequences of the present invention to promote normal cotransporter function.

10

EXAMPLE XI
CHARACTERIZATION OF THE MECHANISM AND SUBSTRATE
SPECIFICITY OF THE HUMAN ILEAL/RENAL BILE ACID
TRANSPORTER

15 Ion-Dependence of Transport

The ileal/renal bile acid transporter is a secondary active cotransporter, relying on the Na^+ gradient maintained by the basolateral Na^+ - K^+ ATPase to provide the driving force for uptake of bile acids against their concentration gradient. The importance of a Na^+ gradient for bile acid transport was demonstrated with isolated ileal sections, ileal enterocytes, and ileal brush-border membrane vesicles. In those studies, replacing Na^+ with divalent cations or other monovalent cations such as K^+ , Li^+ , Rb^+ , or Cs^+ significantly inhibited active taurocholate transport. While it is not clear how translocation of the Na^+ by the transporter is functionally coupled to bile acid transport, the tight constraints on ion size suggests a specific interaction with the channel-forming transmembrane domains. In contrast to an apparent absolute requirement for Na^+ , ileal bile acid transport has no known anion requirement. However, these studies were performed using animal models such as the rat or guinea pig, and very little is known about the ion requirements of the human ileal/renal bile acid transporter. The availability of the human

- 74 -

ileal/renal bile acid transporter cDNA and transiently-transfected and stable cell lines permits direct study of the transporter's ion requirements and substrate specificity. Representative results from those studies are described below.

COS cells were seeded (1.5×10^6 cells/100 mm dish) in DMEM and transfected the following day with pCMV5-HIBAT or pCMV2- β galactosidase (5 μ g) by the DEAE-dextran method. On day 2, each group of transfected cells was treated with trypsin, pooled, and replated in 24-well culture plates at 7×10^4 cells/well. On day 4, cells were incubated at 37° C for 15 min in Hank's balanced salt solution containing 50 μ M [3 H]taurocholate (0.52 Ci/mmol) and the indicated concentration (See FIG. 1A and FIG. 1B) of NaCl (choline chloride was included as the osmotic replacement for NaCl). The medium was then removed and each cell monolayer was washed three times with ice-cold phosphate-buffered saline containing 0.2% (w/v) bovine serum albumin and 1 mM taurocholate, and once with ice-cold phosphate-buffered saline. The cells were then lysed in 0.1 N NaOH and aliquots were taken to determine protein and cell-associated radioactivity. The results are summarized in FIG. 11A. Values for taurocholate uptake are corrected for nonspecific uptake into pCMV2- β galactosidase transfected COS cells and represent the mean \pm SD of triplicate measurements. Hill plot analysis of the data (inset) indicate that the coupling between Na⁺ and taurocholate is 1:1. One molecule of taurocholate is transported per molecule of Na⁺.

Cation Specificity of Uptake

COS cells were seeded (1.5×10^6 cells/100 mm dish) in DMEM and transfected the following day with pCMV5-HIBAT or pCMV2- β galactosidase (5 μ g) by the DEAE-dextran method. On day 2, each group of transfected cells was

- 75 -

treated with trypsin, pooled, and replated in 24-well culture plates at 7×10^4 cells/well. On day 4, cells were incubated at 37°C for 15 min in Hank's balanced salt solution containing $5 \mu\text{M}$ [^3H]taurocholate (0.76 Ci/mmol) and 137 mM sodium or equal concentrations of potassium, lithium, rubidium, cesium, choline, or tetraethylammonium. The medium was then removed and each cell monolayer was washed three times with ice-cold phosphate-buffered saline containing 0.2% (w/v) bovine serum albumin and 1 mM taurocholate, and once with ice-cold phosphate-buffered saline. The cells were then lysed in 0.1 N NaOH and aliquots were taken to determine protein and cell-associated radioactivity. Values for taurocholate uptake are corrected for nonspecific uptake into pCMV2- β galactosidase transfected COS cells and represent the mean \pm SD of triplicate measurements (See Table 1). Data are also given as percentage of control (uptake in the presence of sodium). When Na^+ was replaced with other small cations like K^+ or organic cations like choline, taurocholate uptake is dramatically reduced.

Table 1. Cation-Specificity of Taurocholate Uptake in HIBAT-Transfected COS Cells.

| Cation | Taurocholate Uptake (pmol/min/mg) | % |
|--------------------|--------------------------------------|-----|
| Sodium | 9.2 ± 0.41 | 100 |
| Potassium | 0.3 ± 0.17 | 3 |
| Lithium | 0.3 ± 0.04 | 3 |
| Rubidium | 0.3 ± 0.09 | 3 |
| Cesium | 0.2 ± 0.01 | 2 |
| Choline | 0.0 ± 0.06 | 0 |
| Tetraethylammonium | 0.1 ± 0.02 | 1 |

- 76 -

Anion Specificity of Uptake

COS cells were seeded (1.5×10^6 cells/100 mm dish) in DMEM and transfected the following day with pCMV5-HIBAT or pCMV2- β galactosidase (5 μ g) by the DEAE-dextran method. On day 2, each group of transfected cells was treated with trypsin, pooled, and replated in 24-well culture plates at 7×10^4 cells/well. On day 4, cells were incubated at 37°C for 15 min in Hank's balanced salt solution containing 5 μ M [3 H]taurocholate (0.52 Ci/mmol) and 137 mM sodium or equal concentrations of sodium acetate, bicarbonate, citrate, phosphate, bromide, or sulfate. The medium was then removed and each cell monolayer was washed three times with ice-cold phosphate-buffered saline containing 0.2% (w/v) bovine serum albumin and 1 mM taurocholate, and once with ice-cold phosphate-buffered saline. The cells were then lysed in 0.1 N NaOH and aliquots were taken to determine protein and cell-associated radioactivity. Values for taurocholate uptake are corrected for nonspecific uptake into pCMV2- β galactosidase transfected COS cells and represent the mean \pm SD of triplicate measurements (See Table 2). Data are also given as percentage of control (uptake in the presence of NaCl). When chloride was replaced by acetate, bicarbonate, citrate, phosphate, bromide, or sulfate, taurocholate uptake was 28%, 108%, 5%, 31%, 83%, and 69%, respectively, of the uptake in the presence of NaCl. These results indicate that other anions may substitute for chloride, although taurocholate uptake is markedly reduced in the presence of acetate, citrate, and phosphate.

- 77 -

Table 2. Anion-Specificity of Taurocholate Uptake in HIBAT-Transfected COS Cells.

| Anion | Taurocholate Uptake (pmol/min/mg) | % |
|-------------|--------------------------------------|-----|
| Chloride | 7.5 ± 0.7 | 100 |
| Acetate | 2.1 ± 0.2 | 28 |
| Bicarbonate | 8.1 ± 1.0 | 108 |
| Citrate | 0.4 ± 0.04 | 5 |
| Phosphate | 2.3 ± 0.2 | 31 |
| Bromide | 6.2 ± 0.4 | 83 |
| Sulfate | 5.2 ± 0.8 | 69 |

Chemical Specificity of Transport

It is the ileal/renal bile acid transporter system's remarkable substrate specificity that makes it an appealing pharmacological target for the treatment of hypercholesterolemia by interrupting the enterohepatic circulation of bile acids. A preliminary examination of HIBAT's transport specificity is shown in Table 3. When ileal transport of the major bile acids was examined in rats and humans, the apparent V_{max} and K_m varied with the number of hydroxyl groups on the steroid nucleus, but were unaffected by conjugation of the bile acid. For the V_{max} and K_m of transport: Trihydroxy > Dihydroxy > Monohydroxy bile acids. These studies of the major bile acid species were later extended in animal model systems to include various chemical derivatives of bile acids. However, the affinity of the human ileal/renal bile acid transporter for these natural bile acids has never been studied systematically. In addition to bile acids, the transport of other organic anions has been studied. As for the bile acid analogs tested, the ileal/renal bile acid transport system possesses a narrow substrate

- 78 -

specificity for organic anions. Cholephilic organic compounds such as phalloidin, bilirubin, indocyanine green and 4,4'-diisothiocyano-2,2'-disulfonic acid stilbene (DIDS), that compete for liver taurocholate uptake were ineffective against the ileal transporter *in vivo*. To extend these findings to humans, the cloned ileal/renal bile acid transporter was transfected into COS cells, and these cells were for used for [³H]taurocholate competition studies. The assay was performed as described above except multiple [³H]taurocholate and inhibitor concentrations were used. The K_m , V_{max} , and K_i values were determined using Eadie-Hofstee and Dixon plot analysis.

Table 3. Substrate Specificity of HIBAT-Transfected COS Cells.

| Bile Acid | Apparent K_i (μM) |
|------------------------|----------------------------|
| Chenodeoxycholate | 3.3 ± 1.9 |
| Taurochenodeoxycholate | 3.2 ± 0.5 |
| Deoxycholate | 6.4 ± 2.5 |
| Taurodeoxycholate | 17.3 ± 3.9 |
| Taurocholate | 26.9 ± 5.7 |
| Tauroursodeoxycholate | 28.4 ± 7.4 |
| Cholate | 41.4 ± 4.9 |
| Ursodeoxycholate | 77.1 ± 17.2 |
| Taurodehydrocholate | - |

EXAMPLE XII

GENERATION OF STABLE CELL LINES EXPRESSING THE HUMAN ILEAL /RENAL BILE ACID TRANSPORTER

To create stable transformants expressing the human ileal/renal bile acid transporter, Chinese hamster ovary (CHO-K1) cells were cultured, transfected with pCMV5-

- 79 -

HISBT, and selected for G418 resistance. For these studies, CHO-K1 cells were maintained in DMEM/F12, 10% (v/v) fetal calf serum, 100 units/ml penicillin and 100 µg/ml streptomycin. The cells were transfected with 9.5 µg/100 mm dish of pCMV5-HISBT (human ileal/renal bile acid transporter expression plasmid) together with 0.5 µg/100 mm dish of pSV₃NEO for G418 antibiotic selection. Two days after transfection, the cells were refed DMEM/F12 media containing 10% (v/v) fetal calf serum, penicillin plus streptomycin, and 700 µg/ml of G418 antibiotic. After approximately 2 weeks, well-defined colonies were picked using cloning rings. The colonies were diluted and transferred to replicate 24 well plates. After allowing the cells to grow for 3 - 5 days, [³H]taurocholate activity was assayed in one of the 24 well plates. Cells that expressed bile acid transport activity that was at least 10-fold over mock-transfected CHO cells were subcloned through two rounds of limiting dilution. During each round, [³H]taurocholate activity was assayed. After 2 rounds of selection, CHO cell lines that expressed [³H]taurocholate activity 50 to 80-fold over background were obtained. The results are summarized in FIG. 12.

25

EXAMPLE XIII**DIAGNOSTIC APPLICATIONS OF THE ILEAL/RENAL
BILE ACID TRANSPORTER cDNA**

30

**The Ileal Bile Acid Transporter as a Candidate Gene for
IBD.**

35

In the course of the cloning and characterization of the ileal bile acid transporter gene (localized to chromosome 13q33), a mutation was identified in a patient (See Example VII, above) with Crohn's Disease (CD). This point mutation in exon 5 inactivates the ileal bile acid transporter. In a small pilot study, 3 out of 20 (15%)

- 80 -

CD patients were found to be heterozygous for the mutation compared to 0 out of 60 (0%) control individuals. To extend these studies to a larger population, 429 individuals including 174 ulcerative colitis (UC) patients, 171 CD patients, 6 indeterminate inflammatory bowel disease (IBD) patients, and 78 ethnicity-matched controls were surveyed for the mutation. Ten individuals out of 429 (2.3%) were found to be heterozygous for the mutation. No homozygotes were found. The distribution of the mutation in the UC, CD, and control individuals was as follows: 3/174 (1.7%) of UC patients, 4/171 (2.3%) of CD patients, and 3/78 control individuals (3.8%). These results argue that the ileal bile acid transporter mutation is not associated with IBD in the general population, but does not exclude a role of the transporter mutation in familial IBD.

Biochemical analysis of the mutation indicated that the polymorphism completely abolished transport function. Since the CD in this patient involved mainly the ileum, it was possible that the ileal bile acid transporter mutation played a role in the etiology or progression of the disease.

CD and UC patients were recruited from the surgical service at the Bowman Gray School of Medicine to examine whether the ileal bile acid transporter mutation was common in patients with Crohn's disease. These patients were undergoing ileal resection or colectomy for unrelenting disease. The diagnosis of CD or UC was confirmed using the patient's medical history and evaluation of the resected bowel by the attending pathologist. Ileal tissue was taken for analysis of the bile acid transporter protein and mRNA. Genomic DNA was isolated from surgical specimens or lymphocytes from preoperative blood samples. The presence of the mutation was scored using SSCP (Single Stranded Conformation

- 81 -

Polymorphism) analysis with oligonucleotides flanking the mutation in exon 5 of the ileal bile acid transporter gene. For the first pilot study in the CD patients undergoing ileal resection, two individuals out of nine
5 were found to be heterozygous for the mutation. Ten additional patients were recruited from the GI service who had been diagnosed with CD. Blood was drawn for genomic DNA isolation from buffy coat cells. No additional mutations were found. Including the original
10 proband, 3 individuals out of 20 patients with CD were heterozygous for the ileal bile acid transporter mutation. To determine the frequency of this mutation in the general population, the DNA from 60 normolipidemic caucasian individuals was surveyed for the mutation.
15 None of these "control" individuals were positive for the mutation.

Summary of Pilot Study:

| | | | |
|----|------|-------|--------------------------------|
| 20 | 3/20 | (15%) | All CD patients |
| | 3/10 | (30%) | CD patients undergoing surgery |

Based on these promising results and the biology of the ileal transporter mutation, analysis of a larger
25 population was initiated in collaboration with Dr. Jerome Rotter at the Cedar-Sinai Medical Center in Los Angeles, CA.

Genomic DNA was prepared from 429 transformed
30 lymphocyte cell pellets and used for the SSCP assay. Out of the 429 samples, 10 individuals were identified who were heterozygous for the mutation. The study was done in a blinded fashion, so that the identity of the control, CD, and UC patients was not known to the
35 researchers performing the DNA analysis. After the analysis, the code was broken and the results were tabulated.

- 82 -

Summary of Large Study:

| | | | |
|---|-------|--------|--------------------------|
| | 3/174 | (1.7%) | UC Patients |
| | 4/171 | (2.3%) | CD Patients |
| 5 | 3/78 | (3.8%) | Controls |
| | 0/6 | (0%) | IBD (UC or CD - unknown) |

These results indicate that the mutation is not associated with IBD in the general population. It is not clear why such a high frequency for the mutation was observed for CD patients from the North Carolina area. The patients were unrelated and lived in different regions of the state. The samples were prepared and assayed in a different laboratory and at a different institution than where the cloning and characterization of the ileal bile acid transporter was performed. This makes it unlikely that sample contamination was a confounding factor. The high frequency observed may have been due to the small sample size or bias in selection of the population. However, it cannot be excluded that the mutation may play a role in familial IBD. Further studies utilizing the sequences disclosed herein will assess the frequency of ileal/renal bile acid transporter mutations in IBD patients with a strong family history consistent with an underlying genetic predisposition.

SSCP Assay

To demonstrate the general utility of the invention, the human ileal bile acid transporter cDNA clone was used to generate a Single Stranded Conformation Polymorphism (SSCP) assay to diagnose a point mutation that inactivates the ileal bile acid transporter in patients.

Oligonucleotides flanking the C-to-T transition at human ileal bile acid transporter codon 290 were used to identify the mutation by SSCP analysis. The sequence of

- 83 -

the oligonucleotide pairs used in the polymerase chain reaction were:

- HIBAT 10: 5'-TGAAATGGGATTGGCATGATTCCTT-3', SEQ ID
5 NO:6;
HIBAT 11: 5'-ACACGCAGCTATGTTCCACCATCGT-3', SEQ ID
NO:7;
HIBAT 12: 5'-GCGAGCTGGAAAATGCTGTAGATGA-3', SEQ ID
NO:8;
10 HIBAT 13: 5'-CATGTGCTCTCTTTAACATCTTCTT-3', SEQ ID
NO:9.

See FIG. 13A for positions of the primers. For the SSCP
analysis, the oligonucleotide HIBAT 10 was used in the
15 polymerase chain reaction in combination with HIBAT 11.
The oligonucleotide HIBAT 12 was used in the polymerase
chain reaction in combination with HIBAT 13. The
polymerase chain reaction was performed in a final volume
of 20 μ l with approximately 100 ng of human genomic DNA,
20 1 nmol of dNTPs, 35 pmol of each 25-bp flanking primer,
3.3 pmol [32 P]dCTP (3000 Ci/mmol), and 2.5 Units of Taq
polymerase. The sample was amplified using 1 cycle of
96°C X 5 minutes (hot start) and 72°C X 5 minutes
(addition of Taq polymerase) followed by 30 cycles of
25 96°C X 1 min for denaturation and 68°C X 5 min for
annealing and extension. After amplification, 2 μ l of
the PCR was diluted into 20 μ l of formamide dye (95%
(v/v) formamide, 20 mM EDTA, 0.05% (w/v) bromphenol blue,
0.05% (w/v) xylene cyanol). The sample was denatured at
30 95°C for 5 min, and 4 μ l was loaded onto an 8% (w/v) \ddagger
nondenaturing polyacrylamide gel containing 10% (v/v)
glycerol and 2X TBE (1X TBE = 50 mM Tris-Cl, 50 mM boric
acid, and 1 mM EDTA). The gel was run at 350 volts
(constant voltage) at room temperature for 20 h, dried,
35 and exposed to X-ray film for 20 h at -70°C with an
intensifying screen. (See FIG. 13B)

- 84 -

Evaluation of Ileal/Renal Bile Acid Transporter Mutation in Crohn's Disease and Ulcerative Colitis Patients

Genomic DNA was prepared from 429 transformed lymphocyte cell pellets and used for the SSCP assay. Out of the 429 samples, 10 individuals were identified who were heterozygous for the mutation. The study was done in a blinded fashion, so that the identity of the control, CD, and UC patients was not known to the researchers performing the DNA analysis. After the analysis, the code was broken and the results were tabulated. FIG. 14 shows the SSCP patterns for the 10 individuals identified in this study (lanes 5 - 14). As a positive control, lane 4 shows the SSCP pattern for SH. SH is the original patient diagnosed with a bile acid transporter mutation. Lanes 1-3, and 15-16 show the SSCP pattern from individuals lacking the bile acid transporter mutation. The SSCP analysis was performed with oligonucleotides HIBAT 10 and HIBAT 11, as described above.

Evaluation of Ileal/Renal bile Acid Transporter Mutation in a Family with Crohn's Disease

In the course of screening 171 Crohn's disease patients provided by Dr. Jerome Rotter (Cedar-Sinai Medical Center in Los Angeles, CA.) for the mutation in codon 290 (Proline to Serine mutation), a patient was discovered with the mutation who had multiple family members affected with Crohn's disease. In this family, all three children were diagnosed with Crohn's disease while both parents were unaffected. Analysis of the entire family revealed that all 3 affected children and the father carry the ileal/renal bile acid transporter mutation. Although cosegregation of the mutation and Crohn's disease in one family is insufficient to determine an association, it does provide pilot data for

- 85 -

more extensive family studies. FIG. 15 shows the pedigree and the SSCP analysis of the Crohn's disease family. The SSCP analysis was carried out with oligonucleotides HIBAT 10 and HIBAT 11 as described above. The SSCP banding patterns for each individual appears directly under their depiction in the upper portion of the figure. (WT = Proline at codon 290 of the ileal/renal bile acid transporter; Mut = Serine at codon 290 of the ileal/renal bile acid transporter.

The father is considered a carrier for the mutation since he lacks the clinical manifestations of Inflammatory Bowel Disease. It is presently unknown why the father is unaffected despite carrying the mutation. It is likely that a second mutation or other factor such as diet or viral/bacterial infection may be necessary for clinical manifestation of the disorder. This is not unexpected since there are very few documented monogenic disorders.

Summary of (CA)_n Alleles Linked to Human Ileal/Renal Bile Acid Transporter Gene

Whereas SSCP analysis is useful for the identification of specific mutations, the presence of multiple mutations scattered throughout the gene limits SSCP's utility for screening the population or families with disorders possibly linked to the ileal/renal bile acid transporter. For such screening purposes, a polymorphic marker linked to the ileal/renal bile acid transporter gene is more useful. A rich source of such genetic markers are simple sequence length polymorphisms (SSLPs) or microsatellites. These highly polymorphic sequence repeats are widely distributed throughout the genome and can be efficiently analyzed by PCR.

- 86 -

To obtain such a polymorphic marker, P1 clones harboring the ileal/renal bile acid transporter gene were obtained from a commercially available library (Genome Systems, St. Louis, MO) using the human ileal/renal bile acid transporter sequences as PCR probes. The isolation and characterization of a polymorphic dinucleotide repeat linked to the human ileal/renal bile acid transporter is outlined below.

P1 clones bearing the human ileal bile acid transporter gene were digested with Eco RI and subcloned into pBluescript®. Clones were screened for CA repeat sequences by hybridization with a poly(dA-dC)-poly(dG-dT) probe that was labeled with [³²P]dCTP by the random hexamer procedure. Hybridization was performed in 50% (v/v) formamide, 5 X SSC, 50 mM NaPhosphate pH 6.8, 1 X Denhardtts, and 100 µg/ml salmon sperm DNA at 42°C followed by washing at 60°C in 0.2 X SSC and 0.1% (w/v) SDS. One clone (#2376-1) containing a 5.3 kb insert was isolated that hybridized to the CA repeat probe. After sequential digestions with Hind III and then Hinf I, a 0.25 kb fragment was identified from clone #2376-1 that strongly hybridized to the CA repeat probe. After filling in the ends with Klenow DNA polymerase, the fragment was subcloned into Sma I-digested pBluescript®. The isolated clone, 2376-1A, was subjected to sequence analysis and demonstrated a continuous array of (CA)₁₇. Primers flanking this sequence were designed and used to direct PCR from unrelated subjects:

primer CAF: 5'-AAGTTATTTTGTAGTTCTAATGTTC-3', SEQ ID NO:10;

primer CAR: 5'-GAAACATATATTCATCAGATCAC-3', SEQ ID NO:11.

Genomic DNA was prepared from venous blood of patients by standard methods. PCR was conducted in 15 µl

- 87 -

containing 50 mM KCl, 1.5 mM MgCl₂, 20 mM Tris-HCL pH 8.4, 0.2 mM dNTPs, 23 μ M CAF and CAR, 50 nM of CAR labeled at the 5' end with [³²P], and 100 ng of human genomic DNA. After an initial denaturation step at 96°C for 5 min, PCR was conducted for 10 cycles with denaturation at 94°C for 1 min, annealing at 55°C for 1 min, and extension at 72°C for 1 min followed by 15 cycles with denaturation at 92°C for 1 min, annealing at 55°C for 1 min, and extension at 72°C for 1 min. Genotypes were analyzed by denaturation of the products followed by electrophoresis on standard 6% polyacrylamide-8M urea DNA sequencing gels and subsequent autoradiography.

Analysis of 78 unrelated caucasian individuals revealed that the marker was polymorphic with at least 9 alleles. The heterozygosity was 78% with a calculated PIC (Polymorphism Information Content) of 0.75. FIG. 16 shows samples from heterozygotes exhibiting the 9 alleles identified to date. The ease of analysis, large number of alleles, and high degree of heterozygosity indicate that this marker will be useful for analyzing the genetic association of the ileal/renal bile acid transporter with inherited disease states.

EXAMPLE XIV

Localization of Ileal Sodium-Bile Acid Cotransporter to Human Chromosome 13q33.

Previous studies using DNA from the NIGMS Human/Rodent Cell Hybrid Mapping Panel No. 1 localized the ISBT gene to autosome 13. To determine the precise localization of the ISBT gene on human chromosome 13, high-resolution fluorescence *in situ* hybridization was performed using a method for mapping genes directly on banded chromosomes. For these studies, the hamster ISBT cDNA (Wong et al., 1994) was used to isolate a human

- 88 -

ISBT cDNA clone (1HISBT13) from a human ileal λ gt10 cDNA library. The 1032 nucleotide ISBT coding sequence probe was labeled with digoxigen-11-dUTP (Boehringer Mannheim) or biotin (Bionick, BRL). Slides with well-spread
5 metaphase chromosomes from peripheral blood lymphocytes were treated with RNase A (100 μ g/ml), dehydrated, and denatured at 70°C in 2X SSC and 70% formamide. The probes were resuspended in Oncor hybrisol VI solution and hybridized onto slides for 16-18 h. The ISBT probe was
10 either hybridized singularly or cohybridized with a biotin-labeled Retinoblastoma gene probe (localized to 13q14) (Oncor) and detected as previously described (Rao et al., 1992). Chromosome banding was achieved by incubating the slides with Actinomycin-D (0.3 mg/ml) in
15 McIlvane's/MgCl₂ solution in a humidified chamber at 37°C for 20 min. The slides were counterstained with DAPI. At least 20 metaphases were examined per hybridization using a Zeiss Axiphot microscope equipped with a triple band pass filter (DAPI, FITC, and Rhodamine).

20 Sublocalization to chromosomal region 13q33 was unequivocally made on banded metaphase spreads (FIG. 17). The hybridization was specific and showed paired FITC signals (one for each chromatid); consistent signals were
25 not observed on any other chromosomes. Analysis of interphase cells also showed 1 copy of the ISBT probe. Confirmation of this localization to the long arm of chromosome 13 was achieved by the cohybridization of a probe for the Retinoblastoma gene (FIG. 17, inset).

30 The localization of the ISBT gene to a single locus at 13q33 is concordant with earlier studies of human and human/rodent cell hybrid genomic DNA that indicated the presence of only a single gene residing on chromosome 13.
35 This result clearly distinguishes the ISBT gene from the liver sodium-bile acid cotransporter that was recently localized to human chromosome 14 (Hagenbuch and Meier,

- 89 -

1994). The identification of the human ISBT cDNA and precise determination of its chromosomal location will aid in clarifying the relationship between the ISBT locus and autosomal inherited disorders of bile acid and cholesterol metabolism.

* * *

All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the composition, methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

- 90 -

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details
5 supplementary to those set forth herein, are specifically incorporated herein by reference.

- Andersson, S., Davis, D.L., Dahlback, H., Jornvall, H.,
and Russell, D.W. (1989) *J. Biol. Chem.* 264, 8222-8229.
- 10 Baldwin, J.M. (1993) *EMBO J.* 12, 1693-1703.
- Barnard, J.A., and Grishan, F.K. (1987) *Gastroenterology*
93, 925-933.
- 15 Blobel, G., and Dobberstein, B. (1975) *J. Cell Biol.* 67,
852-862.
- Boyer, J.L., Graf, J., and Meier, P.J. (1992) *Ann. Rev.*
20 *Physiol.* 54, 415-438.
- Briggs, M.S., Yokoyama, C., Wang, X., Brown, M.S. and
Goldstein, J.L. (1993) *J. Biol. Chem.* 268, 14490-14496.
- 25 Buchwald, H., Varco, R.L., Matts, J.P. et al. (1990) *N.*
Enl. J. Med. 323, 946-955.
- Chandler, C.E., Zaccaro, L.M., and Moberly, J.B. (1993)
Am. J. Physiol. 27, G1118-G1125.
- 30 Chirgwin, J.M., Przybyla, A.E., MacDonald, and Rutter,
W.J. (1979) *Biochemistry* 18, 5294-5299.
- Church, G.M., and Gilbert, W. (1984) *Proc. Natl. Acad.*
35 *Sci. U.S.A.* 81, 1991-1995.

The Cold Spring Harbor Manual for Hybridoma Development.

- 91 -

- DeGrip, W.J. (1982) *Methods Enzymol.* 81, 197-207.
- Davis, S., Aldrich, T.H., Valenzuela, D.M., Wong, V.,
Furth, M.E., Squinto, S.P., and Yancopoulos, G.D. (1991)
5 *Science* 253, 59-63.
- Deguchi, Y., Yamamoto, I., and Anraku, Y. (1990) *J. Biol.*
Chem. 265, 21704-21708.
- 10 Devereux, J., Haeberli, P., and Smithies, O. (1984)
Nucl. Acids Res. 12, 387-395.
- Dietschy, J.M. (1968) *J. Lipid Res.* 9, 297-309.
- 15 Ercolani, L., Florence, B., Denaro, M., and Alexander, M.
(1988) *J. Biol. Chem.* 263, 15335-15341.
- Esser, V., Limbird, L.E., Brown, M.S., Goldstein, J.L.,
and Russell, D.W. (1988) *J. Biol. Chem.* 264, 8222-8229.
- 20 Fliesler, S.J. and Basinger, S.F. (1985) *Proc. Natl.*
Acad. Sci. U.S.A. 82, 1116-1120.
- Fricker, G., Kramer, W., Buscher, H.-P., Gerok, W., and
25 Kurz, G. (1982) *Hopp Seylers Z Physiol Chem* 363, 897-905.
- Ghosh-Choudhury and Graham (1987) *Biochem. Biophys. Res.*
Comm. 147:964-973.
- 30 Gluzman et al., (1982) in *Eukaryotic Viral Vectors*
(Gluzman, Y., Ed.) pp. 187-192, Cold Spring Harbor Press,
Cold Spring Harbor, New York.
- Gong, Y.-Z., Zwarych, P.P., Lin, M.C. and Wilson F.A.
35 (1991) *Biochem. Biophys. Res. Comm.* 179, 204-209.

- 92 -

Goodman, D.S. and the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (1988) NIH Publication No. 88-2925.

- 5 Hagenbuch, B., Stieger, B., Foguet, M., Lubbert, H., and Meier, P.J. (1991) *Proc. Natl. Acad. Sci. U.S.A.* **88**, 10629-10633.
- Hagenbuch, B., and Meier, P.J. (1994) *J. Clin. Invest.*
10 **93**: 1326-1331.
- Harlow, E. and D. Lane, *Antibodies "A Laboratory Manual,"* Cold Spring Harbor Laboratory, 1988.
- 15 Heubi, J.E., Balistreri, W.F., Fondacaro, J.P., Partin, J.C. and Schubert, W.K. (1982) *Gastroenterology* **83**, 804-811.
- Hobbs, H.H., Leitersdorf, E., Leffert, C.C., Cryer, D.R.,
20 Brown, M.S., and Goldstein, J.L. (1989) *J. Clin. Invest.* **84**: 656-664.
- Hofmann, A.F. (1977) *Clinics in Gastroenterology* **63**, 3-24.
25
- Hofmann, A.F. (1989) in Gastrointestinal Disease, pp. 144-161.
- Hofmann, A.F. (1993). The enterohepatic circulation of
.30 bile acids in health and disease. In "Gastrointestinal Disease. Pathophysiology, Diagnosis, Management" (M.H. Sleisenger and J.S. Fordtran, Eds.), pp. 127-150, Saunders, Philadelphia.
- 35 Jacquemin, E., Hagenbuch, B., Steiger, B., Wolkoff, A.W. and Meier, P.J. (1992) *Hepatology* **16**, 89A.

- 93 -

- Khorana, H.G. (1992) *J. Biol. Chem.* 267, 1-4.
- Kozak, M. (1987) *Nucl. Acids Res.* 15, 8125-8148.
- 5 Krag, E. and Phillips, S.F. (1974) *J. Clin. Invest.* 53, 1686-1694.
- Kramer, W., Burckhardt G., Wilson, F.A. and Kurz, G. (1983) *J. Biol. Chem.* 258, 3623-3627.
- 10 Kramer, W., Nicol, S-B., Girbig, F., Gutjahr, U., Kowalewski, S., and Fasold, H. (1992) *Biochim. Biophys. Acta* 1111, 93-102.
- 15 Kyte, J., and Doolittle, R.F. (1982) *J. Mol. Biol.* 157, 105-132.
- Lack, L. and Weiner, I.M. (1961) *Am. J. Physiol.* 200, 313-317.
- 20 Lack, L. (1979) *Environ. Health Perspect.* 33, 79-90.
- Lewis, M.C., and Root, C. (1990) *Am. J. Physiol.* 259, G233-238.
- 25 Lin, M.C., Weinberg, S.L., Kramer, W., Burckhardt, G. and Wilson, F.A. (1988) *J. Membr. Biol.* 106, 1-11.
- Lin, M.C., Kramer, W., and Wilson, F.A. (1990) *J. Biol.*
- 30 *Chem.* 265, 14986-14995.
- Marcus, S.N., Schteingart, C.D., Marquez, M.L., Hofmann, A.F., Xia, Y., Steinbach, J.H., Ton-Nu, H-T., Lillienau, J., Angellotti, M.A., and Schmassmann, A. (1991)
- 35 *Gastroenterology* 100, 212-221.
- McGrory, W.J. et al. (1988). *Virology* 163:614-617.

- 94 -

- Miller 1992, *Curr. Top. Microbiol. Immunol.* 158:1
- Mullins, J.G.L., Beechey R.B., Gould G.W., Campbell, F.C., and Shirazi-Beechey, S.P. (1992) *Biochem. J.* 285, 785-790.
- Rao, P.N., Hayworth, R., Akots, G., Pettenati, M.J., and Bowden, D.W. (1992). *Genomics* 14: 532-535.
- Read, N.W., Krejs, G.J., Read, M.G., Santa Ana, C.A., Morawski, S.G. and Fordtran, J.S. (1980) *Gastroenterology* 78, 264-271.
- Russell, D.W., and Setchell, K.D.R. (1992) *Biochemistry* 31, 4737-4749.
- Saiki, R.K., Gelfand, D.H., Stoffel, S., Scharf, S.J., Higuchi, R., Horn, G.T., Mullis, K.B., and Erlich, H.A. (1988) *Science* 239, 487-491.
- Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
- Schiff, E.R., Small, N.C., and Dietschy, J.M. (1972) *J. Clin. Invest.* 51, 1351-1362.
- Schwenk, M., Hegazy, E., and Lopez del Pino, V. (1983) *Eur. J. Biochem.* 131, 387-391.
- Sorscher, S., Lillienau, J., Meinkoth, J.L., Steinbach, J.H., Scheingart, C.D., Feramisco, J., and Hofmann, A.F. (1992) *Biochem Biophys. Res. Comm.* 186, 1455-1462.
- U.S. Pat. No 4,196,265.
- U.S. Patent 4,603,102.

- 95 -

- Von Dippe, P., Amoul, M. and Levy, D. (1993) *Am. J. Physiol.* 264, G528-G534.
- von Heijne, G. (1983) *Eur. J. Biochem.* 133, 17-21.
- 5 Weinberg, S.L, Burckhardt, G., and Wilson, F.A. (1986) *J. Clin. Invest.* 78, 44-50.
- Weiner, I.M., Glasser, J.E., and Lack, L. (1964) *Am. J. Physiol.* 207, 964-970.
- 10 Wilson, F.A. and Dietschy, J.M. (1974) *Biochim. Biophys. Acta* 363, 112-126.
- 15 Wilson, F.A. and Treanor, L.L. (1979) *Biochim. Biophys. Acta* 554, 430-440.
- Wilson, F.A. (1981) *Am. J. Physiol.* 241, G83-92.
- 20 Wilson, F.A., Burckhardt, G., Murer, H., Rumrich, G., and Ullrich, K.J. (1981) *J. Clin. Invest.* 67, 1141-1150.
- Wong, M.H., Oelkers P., Craddock, A.L., and Dawson P.A. (1994). *J. Biol. Chem.* 269: 1340-1347.
- 25 Wright, E.M., Hager K.M., and Turk E. (1992) *Curr. Opin. Cell Biol.* 4, 696-702.
- Zimmerli, B., Valantinas, J., and Meier, P.J. (1989) *J. Pharmacol. Exp. Ther.* 250, 301-308.
- 30

- 96 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5

(i) APPLICANT:

- (A) NAME: WAKE FOREST UNIVERSITY
- (B) STREET: MEDICAL CENTER BOULEVARD
- (C) CITY: WINSTON-SALEM
- 10 (D) STATE: NORTH CAROLINA
- (E) COUNTRY: UNITED STATES OF AMERICA
- (F) POSTAL (ZIP) CODE: 27517-1023

15

(ii) INVENTORS: DAWSON, Paul A.

(iii) TITLE OF INVENTION: ILEAL BILE ACID TRANSPORTER
COMPOSITIONS

20

(iv) NUMBER OF SEQUENCES: 11

(v) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: Arnold, White & Durkee
- (B) STREET: P. O. Box 4433
- (C) CITY: Houston
- 25 (D) STATE: Texas
- (E) COUNTRY: United States of America
- (F) ZIP: 77210

30

(vi) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS/ASCII
- (D) SOFTWARE: PatentIn Release #1.0, Version
#1.25

35

(vii) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER: Unknown

- 97 -

(B) FILING DATE: Concurrently herewith

(C) CLASSIFICATION: Unknown

(viii) PRIOR APPLICATION DATA:

5 (A) APPLICATION NUMBER: USSN 08/176,126

(B) FILING DATE: 29-DEC-1993

(C) CLASSIFICATION: Unknown

(ix) ATTORNEY/AGENT INFORMATION:

10 (A) NAME: PARKER, DAVID L.

(B) REGISTRATION NUMBER: 32,165

(C) REFERENCE/DOCKET NUMBER: WAKE005P--

(x) TELECOMMUNICATION INFORMATION:

15 (A) TELEPHONE: (512) 418-3000

(B) TELEFAX: (713) 789-2679

(C) TELEX: 79-0924 (1) GENERAL INFORMATION:

20 (2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2263 base pairs

(B) TYPE: nucleic acid

25 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

30 (ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 109..1152

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

- 98 -

GGTTTAAAG TTTGACGTGC TCACCAGGTG CTACTCAGCT GCCAGTGGGT AGAGAACCGA 60

GGACAGGTGC TTCTGTGGGG CTTGACTGTT TACACAGCAC AGCCAGAG ATG GAT AAC 117
Met Asp Asn
1

TCC TCC ATC TGC AAC CCC AAC GCG ACC ATC TGC GAA GGC GAC TCC TGC 165
Ser Ser Ile Cys Asn Pro Asn Ala Thr Ile Cys Glu Gly Asp Ser Cys
5 10 15

ATA GCA CCG GAG AGC AAC TTC AAC GCC ATC CTC AGC GTG GTG ATG AGC 213
Ile Ala Pro Glu Ser Asn Phe Asn Ala Ile Leu Ser Val Val Met Ser
20 25 30 35

ACC GTG CTC ACA ATC CTC CTA GCC TTG GTG ATG TTT TCC ATG GGG TGC 261
Thr Val Leu Thr Ile Leu Leu Ala Leu Val Met Phe Ser Met Gly Cys
40 45 50

AAT GTG GAA CTC CAC AAG TTT CTG GGA CAC CTA AGG CGG CCA TGG GGC 309
Asn Val Glu Leu His Lys Phe Leu Gly His Leu Arg Arg Pro Trp Gly
55 60 65

- 99 -

ATC GTC GTG GGC TTC CTC TGT CAG TTT GGA ATC ATG CCT CTC ACA GGT 357
 Ile Val Val Gly Phe Leu Cys Gln Phe Gly Ile Met Pro Leu Thr Gly
 70 75 80

5 TTC GTC CTG TCC GTG GCC TTT GGC ATC CTC CCA GTG CAA GCT GTG GTG 405
 Phe Val Leu Ser Val Ala Phe Gly Ile Leu Pro Val Gln Ala Val Val
 85 90 95

GTG CTG ATC CAG GGT TGC TGC CCT GGA GGA ACT GCC TCC AAT ATC CTA 453
 10 Val Leu Ile Gln Gly Cys Cys Pro Gly Gly Thr Ala Ser Asn Ile Leu
 100 105 110 115

GCC TAT TGG GTA GAT GGC GAC ATG GAC CTC AGC GTT AGC ATG ACC ACC 501
 Ala Tyr Trp Val Asp Gly Asp Met Asp Leu Ser Val Ser Met Thr Thr
 15 120 125 130

TGC TCC ACG CTG CTT GCC CTT GGA ATG ATG CCC CTT TGC CTC TTC ATC 549
 Cys Ser Thr Leu Leu Ala Leu Gly Met Met Pro Leu Cys Leu Phe Ile
 135 140 145

20 TAT ACC AAG ATG TGG GTT GAC TCA GGG ACG ATT GTG ATT CCT TAT GAC 597
 Tyr Thr Lys Met Trp Val Asp Ser Gly Thr Ile Val Ile Pro Tyr Asp
 150 155 160

- 100 -

| | | |
|----|---|-----|
| | AGC ATT GGC ACT TCT CTG GTT GCT CTT GTT ATT CCT GTT TCC ATT GGA | 645 |
| | Ser Ile Gly Thr Ser Leu Val Ala Leu Val Ile Pro Val Ser Ile Gly | |
| | 165 170 175 | |
| 5 | ATG TAT GTG AAT CAC AAA TGG CCC CAA AAA GCA AAG ATC ATA CTT AAA | 693 |
| | Met Tyr Val Asn His Lys Trp Pro Gln Lys Ala Lys Ile Ile Leu Lys | |
| | 180 185 190 195 | |
| | ATT GGA TCC ATC GCA GGT GCA ATT CTC ATT GTT CTC ATC GCT GTG GTT | 741 |
| 10 | Ile Gly Ser Ile Ala Gly Ala Ile Leu Ile Val Leu Ile Ala Val Val | |
| | 200 205 210 | |
| | GGA GGA ATA CTG TAC CAA AGT GCC TGG ACC ATT GAA CCC AAG CTG TGG | 789 |
| | Gly Gly Ile Leu Tyr Gln Ser Ala Trp Thr Ile Glu Pro Lys Leu Trp | |
| 15 | 215 220 225 | |
| | ATT ATA GGA ACC ATA TAT CCT ATA GCT GGC TAC GGC CTG GGG TTT TTC | 837 |
| | Ile Ile Gly Thr Ile Tyr Pro Ile Ala Gly Tyr Gly Leu Gly Phe Phe | |
| | 230 235 240 | |
| 20 | CTG GCT AGA ATT GCT GGT CAA CCC TGG TAC AGG TGC CGA ACA GTT GCC | 885 |
| | Leu Ala Arg Ile Ala Gly Gln Pro Trp Tyr Arg Cys Arg Thr Val Ala | |
| | 245 250 255 | |

-101-

TTG GAA ACC GGG TTG CAG AAC ACT CAG CTG TGT TCC ACC ATT GTG CAG 933
 Leu Glu Thr Gly Leu Gln Asn Thr Gln Leu Cys Ser Thr Ile Val Gln
 260 265 270 275

5 CTT TCC TTC AGC CCT GAG GAC CTC AAC CTT GTG TTC ACC TTC CCC CTC 981
 Leu Ser Phe Ser Pro Glu Asp Leu Asn Leu Val Phe Thr Phe Pro Leu
 280 285 290

ATC TAC AGC ATC TTC CAG ATC GCC TTT GCA GCA ATA CTA TTA GGA GCT 1029
 10 Ile Tyr Ser Ile Phe Gln Ile Ala Phe Ala Ala Ile Leu Leu Gly Ala
 295 300 305

TAT GTC GCA TAC AAG AAA TGT CAT GGA AAA AAT AAT ACT GAG CTA CAA 1077
 Tyr Val Ala Tyr Lys Lys Cys His Gly Lys Asn Asn Thr Glu Leu Gln
 310 315 320

GAG AAA ACA GAC AAT GAA ATG GAG CCC AGG TCA TCA TTT CAG GAG ACA 1125
 Glu Lys Thr Asp Asn Glu Met Glu Pro Arg Ser Ser Phe Gln Glu Thr
 325 330 335

AAC AAA GGA TTT CAA CCA GAT GAG AAG TAAAACTAA GGGGACAGAA 1172
 Asn Lys Gly Phe Gln Pro Asp Glu Lys
 340 345

-102-

1232 AAGAAAGCTT ACTAACAACA TTCATTAAAC TACAAC TATT TCATTGGTG GAATGATCAG
1292 CAGAAAAAAA TGTTTAAAAAT TCAATTGCGAA ATTTGTTATT GTTTTGGTAC AAAGTGACTA
5 1352 GCAATCCATT CTTTATTGTG ACAAACATCT GAGAGAGAGA GAGAGAGATA GAGAGAGAGA
1412 GAGAGAGAGA GAGAGAGAGA GAGAGAGAGA GAGAGAGAGA GTGTGTGTGT GTGTAGAGTG
1472 TGTACATATC CACAGGGGAC TGACTGGTCA CAGGATATCC CTTGATACTA AATTCACAGA
10 1532 AGCATGAGCT TCCTTCATAA AATGGCAAAA TGTTTGCATT CATCTCTCAT ATACTTCAGA
1592 TCAATACTAA CTTACTTAAA ATATTTAACA TGATGTAAAT GCTATGTAAA TAGTCATTTT
1652 ACTGTATTGT TTAGGAAATG ATGTTTTTTTTT AAGTCTGTGA TATTTTATGT TCAGTACAGA
1712 CATCATTTTT CCTGAAAATT TTGACAAAAAG TGGGACTTAT CCATAGAGTT CAAACTTATT
1772 CTTGGGAGGA AAAC TGAATT TACATAGATA GATATGATCA ATCATCACTA ATATATTATC
20 1832 AGAAAAATATC TAAAGACCTA ACTGAATGTA GATCAGACTG GAAACCTTGT TATAGTATGC
1892 TGAATTCAGA AACAAAGCACT TTTATATGTT AAAATATAAC AGATTATTAT TATAAAATGT

-103-

1952 TGATTTTCTT CAGTATTAT GATTGTAAA AGATGTGAAT GAATGTATTC CTTAATATT
2012 TTAATCATCA GTTTGAGACT CTGCAACCTA TTTATTTGTG ATGTTTACAC TATACTCTGT
2072 5 CAAGTGCTG TCTTTTACT TTAGAAAAGT GGCTTCTTTC AGTGATATTC CAAAAGCAGA
2132 AGTGAGATAA AGATTACTAA TGAATTCAAT AACAAATCAG AATTGAGTTA AACTCACCAC
2192 GGATATTTTA CATCCGTTCA CATACTTCTA TGGTCCACCA ATGACCACTA TATCTTTTCA
2252 10 GGAAAAGACC TCATTAGAAC AGTTTATATC TGGCAACTTA GTTTGTTGAA CTCTAGAGAT
2263 GTTTACTAAA G

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 348 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

- 104 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

| | | |
|----|---|-----|
| 1 | Met Asp Asn Ser Ser Ile Cys Asn Pro Asn Ala Thr Ile Cys Glu Gly | 15 |
| 5 | | |
| 20 | Asp Ser Cys Ile Ala Pro Glu Ser Asn Phe Asn Ala Ile Leu Ser Val | 30 |
| | | |
| 10 | Val Met Ser Thr Val Leu Thr Ile Leu Leu Ala Leu Val Met Phe Ser | 45 |
| | | |
| 50 | Met Gly Cys Asn Val Glu Leu His Lys Phe Leu Gly His Leu Arg Arg | 60 |
| | | |
| 15 | Pro Trp Gly Ile Val Val Gly Phe Leu Cys Gln Phe Gly Ile Met Pro | 80 |
| | | |
| 20 | Leu Thr Gly phe Val Leu Ser Val Ala Phe Gly Ile Leu Pro Val Gln | 95 |
| | | |
| | Ala Val Val Val Leu Ile Gln Gly Cys Cys Pro Gly Gly Thr Ala Ser | 110 |

-105-

Asn Ile Leu Ala Tyr Trp Val Asp Gly Asp Met Asp Leu Ser Val Ser
 115 120 125
 Met Thr Thr Cys Ser Thr Leu Leu Ala Leu Gly Met Met Pro Leu Cys
 130 135 140
 Leu Phe Ile Tyr Thr Lys Met Trp Val Asp Ser Gly Thr Ile Val Ile
 145 150 155 160
 Pro Tyr Asp Ser Ile Gly Thr Ser Leu Val Ala Leu Val Ile Pro Val
 165 170 175
 Ser Ile Gly Met Tyr Val Asn His Lys Trp Pro Gln Lys Ala Lys Ile
 180 185 190
 Ile Leu Lys Ile Gly Ser Ile Ala Gly Ala Ile Leu Ile Val Leu Ile
 195 200 205
 Ala Val Val Gly Gly Ile Leu Tyr Gln Ser Ala Trp Thr Ile Glu Pro
 210 215 220
 Lys Leu Trp Ile Ile Gly Thr Ile Tyr Pro Ile Ala Gly Tyr Gly Leu
 225 230 235 240

-106-

Gly Phe Phe Leu Ala Arg Ile Ala Gly Gln Pro Trp Tyr Arg Cys Arg
 245 250 255

Thr Val Ala Leu Glu Thr Gly Leu Gln Asn Thr Gln Leu Cys Ser Thr
 260 265 270

5

Ile Val Gln Leu Ser Phe Ser Pro Glu Asp Leu Asn Leu Val Phe Thr
 275 280 285

Phe Pro Leu Ile Tyr Ser Ile Phe Gln Ile Ala Phe Ala Ala Ile Leu
 290 295 300

10

Leu Gly Ala Tyr Val Ala Tyr Lys Lys Cys His Gly Lys Asn Asn Thr
 305 310 315 320

15

Glu Leu Gln Glu Lys Thr Asp Asn Glu Met Glu Pro Arg Ser Ser Phe
 325 330 335

Gln Glu Thr Asn Lys Gly Phe Gln Pro Asp Glu Lys
 340 345

20

(2) INFORMATION FOR SEQ ID NO:3:

-107-

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1047 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
(B) LOCATION: 1..1044

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

| | | | |
|----|---|---------------------|----|
| 15 | ATG AAT GAT CCG AAC AGC TGT GTG GAC AAT GCA | ACA GTT TGC TCT GGT | 48 |
| | Met Asn Asp Pro Asn Ser Cys Val Asp Asn Ala | Thr Val Cys Ser Gly | |
| | 1 | 5 | 10 |
| | | | 15 |
| | GCA TCC TGT GTG GTA CCT GAG AGC AAT TTC AAT | AAC ATC CTA AGT GTG | 96 |
| 20 | Ala Ser Cys Val Val Pro Glu Ser Asn Phe Asn | Asn Ile Leu Ser Val | |
| | 20 | 25 | 30 |

| | | |
|----|---|-----|
| 5 | ATG GGA TGC AAC GTG GAA ATC AAG AAA TTT CTA GGG CAC ATA AAG CGG | 192 |
| | Met Gly Cys Asn Val Glu Ile Lys Lys Phe Leu Gly His Ile Lys Arg | |
| | 50 55 60 | |
| 10 | CCG TGG GGC ATT TGT GTT GGC TTC CTC TGT CAG TTT GGA ATC ATG CCC | 240 |
| | Pro Trp Gly Ile Cys Val Gly Phe Leu Cys Gln Phe Gly Ile Met Pro | |
| | 65 70 75 80 | |
| 15 | CTC ACA GGA TTC ATC CTG TCG GTG GCC TTT GAC ATC CTC CCG CTC CAG | 288 |
| | Leu Thr Gly Phe Ile Leu Ser Val Ala Phe Asp Ile Leu Pro Leu Gln | |
| | 85 90 95 | |
| 20 | GCC GTA GTG GTG CTC ATT ATA GGA TGC TGC CCT GGA GGA ACT GCC TCC | 336 |
| | Ala Val Val Val Leu Ile Ile Gly Cys Cys Pro Gly Gly Thr Ala Ser | |
| | 100 105 110 | |
| 25 | AAT ATC TTG GCC TAT TGG GTC GAT GGC GAC ATG GAC CTG AGC GTC AGC | 384 |
| | Asn Ile Leu Ala Tyr Trp Val Asp Gly Asp Met Asp Leu Ser Val Ser | |
| | 115 120 125 | |

-109-

432
 ATG ACC ACA TGC TCC ACA CTG CTT GCC CTC GGA ATG ATG CCG CTG TGC
 Met Thr Thr Cys Ser Thr Leu Leu Ala Leu Gly Met Met Pro Leu Cys
 130 135 140

5 480
 CTC CTT ATC TAT ACC AAA ATG TGG GTC GAC TCT GGG AGC ATC GTA ATT
 Leu Leu Ile Tyr Thr Lys Met Trp Val Asp Ser Gly Ser Ile Val Ile
 145 150 155 160

10 528
 CCC TAT GAT AAC ATA GGT ACA TCT CTG GTT GCT CTC GTT GTT CCT GTT
 Pro Tyr Asp Asn Ile Gly Thr Ser Leu Val Ala Leu Val Val Pro Val
 165 170 175

15 576
 TCC ATT GGA ATG TTT GTT AAT CAC AAA TGG CCC CAA AAA GCA AAG ATC
 Ser Ile Gly Met Phe Val Asn His Lys Trp Pro Gln Lys Ala Lys Ile
 180 185 190

20 624
 ATA CTT AAA ATT GGG TCC ATC GCG GGC GCC ATC CTC ATT GTG CTC ATA
 Ile Leu Lys Ile Gly Ser Ile Ala Gly Ala Ile Leu Ile Val Leu Ile
 195 200 205

672
 GCT GTG GTT GGA GGA ATA TTG TAC CAA AGC GCC TGG ATC ATT GCT CCC
 Ala Val Val Gly Gly Ile Leu Tyr Gln Ser Ala Trp Ile Ile Ala Pro
 210 215 220

- 110 -

| | | |
|----|---|-----|
| | AAA CTG TGG ATT ATA GGA ACA ATA TTT CCT GTG GCG GGT TAC TCC CTG | 720 |
| | Lys Leu Trp Ile Ile Gly Thr Ile Phe Pro Val Ala Gly Tyr Ser Leu | |
| | 225 230 235 240 | |
| 5 | GGG TTT CTT CTG GCT AGA ATT GCT GGT CTA CCC TGG TAC AGG TGC CGA | 768 |
| | Gly Phe Leu Leu Ala Arg Ile Ala Gly Leu Pro Trp Tyr Arg Cys Arg | |
| | 245 250 255 | |
| | ACG GTT GCT TTT GAA ACG GGG ATG CAG AAC ACG CAG CTA TGT TCC ACC | 816 |
| 10 | Thr Val Ala Phe Glu Thr Gly Met Gln Asn Thr Gln Leu Cys Ser Thr | |
| | 260 265 270 | |
| | ATC GTT CAG CTC TCC TTC ACT CCT GAG GAG CTC AAT GTC GTA TTC ACC | 864 |
| | Ile Val Gln Leu Ser Phe Thr Pro Glu Glu Leu Asn Val Val Phe Thr | |
| 15 | 275 280 285 | |
| | TTC CCG CTC ATC TAC AGC ATT TTC CAG CTC GCG TTT GCC GCA ATA TTC | 912 |
| | Phe Pro Leu Ile Tyr Ser Ile Phe Gln Leu Ala Phe Ala Ala Ile Phe | |
| | 290 295 300 | |
| 20 | TTA GGA TTT TAT GTG GCA TAC AAG AAA TGT CAT GGA AAA AAC AAG GCA | 960 |
| | Leu Gly Phe Tyr Val Ala Tyr Lys Lys Cys His Gly Lys Asn Lys Ala | |
| | 305 310 315 320 | |

-111-

GAA ATT CCA GAG AGC AAA GAA AAT GGA ACG GAG CCA GAG TCA TCG TTT 1008
Glu Ile Pro Glu Ser Lys Glu Asn Gly Thr Glu Pro Glu Ser Ser Phe 335
325 330

5 TAT AAG GCA AAT GGA GGA TTT CAA CCT GAC GAA AAG TAG 1047
Tyr Lys Ala Asn Gly Gly Phe Gln Pro Asp Glu Lys 345
340

10 (2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 348 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

20

Met Asn Asp Pro Asn Ser Cys Val Asp Asn Ala Thr Val Cys Ser Gly
1 5 10 15

- 112 -

Ala Ser Cys Val Val Pro Glu Ser Asn Phe Asn Ile Leu Ser Val
 20 25 30

Val Leu Ser Thr Val Leu Thr Ile Leu Leu Ala Leu Val Met Phe Ser
 35 40 45

Met Gly Cys Asn Val Glu Ile Lys Lys Phe Leu Gly His Ile Lys Arg
 50 55 60

10 Pro Trp Gly Ile Cys Val Gly Phe Leu Cys Gln Phe Gly Ile Met Pro
 65 70 75 80

Leu Thr Gly Phe Ile Leu Ser Val Ala Phe Asp Ile Leu Pro Leu Gln
 85 90 95

Ala Val Val Val Leu Ile Ile Gly Cys Cys Pro Gly Gly Thr Ala Ser
 100 105 110

Asn Ile Leu Ala Tyr Trp Val Asp Gly Asp Met Asp Leu Ser Val Ser
 115 120 125

Met Thr Thr Cys Ser Thr Leu Leu Ala Leu Gly Met Met Pro Leu Cys
 130 135 140

- 113 -

| | | | | |
|-----|---|---------------------|-----|-----|
| 145 | Leu Leu Ile Tyr Thr Lys Met Trp Val Asp Ser | Gly Ser ile Val Ile | 155 | 160 |
| | 150 | | | |
| 5 | Pro Tyr Asp Asn Ile Gly Thr Ser Leu Val Ala | Leu Val Val Pro Val | 170 | 175 |
| | 165 | | | |
| | Ser Ile Gly Met Phe Val Asn His Lys Trp Pro | Gln Lys Ala Lys Ile | 185 | 190 |
| | 180 | | | |
| 10 | Ile Leu Lys Ile Gly Ser Ile Ala Gly Ala Ile | Leu Ile Val Leu Ile | 200 | 205 |
| | 195 | | | |
| | Ala Val Val Gly Gly Ile Leu Tyr Gln Ser Ala | Trp Ile Ile Ala Pro | 215 | 220 |
| | 210 | | | |
| 15 | Lys Leu Trp Ile Ile Gly Thr Ile Phe Pro Val | Ala Gly Tyr Ser Leu | 230 | 240 |
| | 225 | | | |
| | Gly Phe Leu Leu Ala Arg Ile Ala Gly Leu Pro | Trp Tyr Arg Cys Arg | 245 | 255 |
| 20 | | | | |
| | Thr Val Ala Phe Glu Thr Gly Met Gln Asn Thr | Gln Leu Cys Ser Thr | 260 | 270 |
| | | | | |

- 114 -

Ile Val Gln Leu Ser Phe Thr Pro Glu Glu Leu Asn Val Val Phe Thr
 275 280 285

Phe Pro Leu Ile Tyr Ser Ile Phe Gln Leu Ala Phe Ala Ala Ile Phe
 290 295 300

Leu Gly Phe Tyr Val Ala Tyr Lys Lys Cys His Gly Lys Asn Lys Ala
 305 310 315 320

10 Glu Ile Pro Glu Ser Lys Glu Asn Gly Thr Glu Pro Glu Ser Ser Phe
 325 330 335

Tyr Lys Ala Asn Gly Gly Phe Gln Pro Asp Glu Lys
 340 345

15

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 14 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

-115-

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

5 Ser Phe Gln Glu Thr Asn Lys Gly Phe Gln Pro Asp Glu Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:6:

10

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

20

TGAAATGGGA TTGGCATGAT TCCTT

25

- 116 -

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

ACACGCAGCT ATGTTCCACC ATCGT

25

15

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GCGAGCTGGA AAATGCTGTA GATGA

25

30

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single

- 117 -

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CATGTGCTCT CTTTAACATC TTCTT

25

(2) INFORMATION FOR SEQ ID NO:10:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

15

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

20

AAGTTATTTT TAGTTCTAAT GTTC

24

(2) INFORMATION FOR SEQ ID NO:11:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

30

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

35

GAAACATATA TTCATCAGAT CAC

23

- 118 -

CLAIMS:

1. A nucleic acid segment comprising an isolated gene
5 encoding a mammalian ileal/renal bile acid cotransporter polypeptide.
2. The nucleic acid segment of claim 1 wherein said
10 gene encodes an amino acid sequence in accordance with SEQ ID NO:2 or SEQ ID NO:4.
3. The nucleic acid segment of claim 1, further defined
15 as comprising:
- a nucleic acid sequence in accordance with the
sequence of SEQ ID NO:1 or SEQ ID NO:3; or
- 20 a mammalian ileal/renal bile acid cotransporter coding sequence, wherein the segment hybridizes to (a) under conditions of hybridization in 50% formamide buffer, followed by washing in 0.2 X SSC at 65°C for 30 minutes.
- 25
4. The nucleic acid segment of claim 1, wherein the nucleic acid segment has the sequence of SEQ ID NO:1.
- 30
5. The nucleic acid segment of claim 1, wherein the nucleic acid segment has the sequence of SEQ ID NO:3.

- 119 -

6. The nucleic acid segment of any of claims 1-5, wherein the nucleic acid segment is positioned under the control of a promoter.

5

7. The nucleic acid segment of claim 6, wherein the promoter is further defined as a recombinant promoter.

10

8. The nucleic acid segment of any of claims 1-7, further defined as a recombinant vector.

15

9. The nucleic acid segment of claim 8, wherein the vector comprises a nucleic acid sequence in accordance with SEQ ID NO:1 or SEQ ID NO:3.

20

10. The nucleic acid segment of claim 9, wherein the vector is a recombinant expression vector capable of expressing an ileal/renal bile acid transporter polypeptide on introduction into a host cell.

25

11. A nucleic acid segment which comprises a sequence region of at least a 17 nucleotide long contiguous sequence that has the same sequence as, or is complementary to, a 17 nucleotide long contiguous sequence of SEQ ID NO:1 or SEQ ID NO:3.

30

12. The nucleic acid segment of claim 11, wherein the sequence region consists of at least a 25 nucleotide long contiguous sequence that has the same sequence as, or is complementary to, a 25 nucleotide long contiguous sequence of SEQ ID NO:1 or SEQ ID NO:3.

35

- 120 -

13. The nucleic acid segment of claim 12, wherein the sequence region consists of at least a 30 nucleotide long contiguous sequence that has the same sequence as, or is
5 complementary to, a 30 nucleotide long contiguous sequence of SEQ ID NO:1 or SEQ ID NO:3.

14. The nucleic acid segment of claim 13, wherein the
10 sequence region consists of at least a 50 nucleotide long contiguous sequence that has the same sequence as, or is complementary to, a 50 nucleotide long contiguous
sequence of SEQ ID NO:1 or SEQ ID NO:3.

15. The nucleic acid segment of claim 14, wherein the sequence region consists of at least a 100 nucleotide long contiguous sequence that has the same sequence as, or is complementary to, a 100 nucleotide long contiguous
20 sequence of SEQ ID NO:1 or SEQ ID NO:3.

16. The nucleic acid segment of claim 15, wherein the sequence region consists of at least a 1000 nucleotide
25 long contiguous sequence that has the same sequence as, or is complementary to, a 1000 nucleotide long contiguous sequence of SEQ ID NO:1 or SEQ ID NO:3.

17. The nucleic acid segment of claim 16, wherein the
30 sequence region consists of at least a 1044 nucleotide long contiguous sequence that has the same sequence as, or is complementary to, a 1044 nucleotide long contiguous sequence of SEQ ID NO:1 or SEQ ID NO:3.

35

- 121 -

18. The nucleic acid segment of claim 17, wherein the sequence region consists of at least a 1047 nucleotide long contiguous sequence that has the same sequence as, or is complementary to, a 1047 nucleotide long contiguous sequence of SEQ ID NO:1 or SEQ ID NO:3.

19. The nucleic acid segment of claim 18, wherein the sequence region consists of at least a 2263 nucleotide long contiguous sequence that has the same sequence as, or is complementary to, a 2263 nucleotide long contiguous sequence of SEQ ID NO:1.

20. The nucleic acid segment of claim 11, further defined as being up to 10,000 basepairs in length.

21. The nucleic acid segment of claim 20, further defined as being up to 5,000 basepairs in length.

22. The nucleic acid segment of claim 21, further defined as being up to 3,000 basepairs in length.

23. The nucleic acid segment of claim 22, further defined as being up to 1,000 basepairs in length.

24. The nucleic acid segment of claim 23, further defined as being up to 500 basepairs in length.

25. The nucleic acid segment of claim 24, further defined as being up to 100 basepairs in length.

- 122 -

26. The nucleic acid segment of claim 25, further defined as being up to 50 basepairs in length.

5

27. A nucleic acid segment comprising the complement to the nucleic acid segment of any of claims 1-26.

10

28. A recombinant host cell comprising a nucleic acid segment in accordance with any of claims 1-27.

15

29. The recombinant host cell of claim 28, wherein the host cell is a eukaryotic cell.

20

30. The nucleic acid segment of any of claims 1-29, further defined as a DNA segment.

31. A polypeptide comprising an amino acid sequence according to SEQ ID NO:2 or SEQ ID NO:4.

25

32. The polypeptide of claim 31 wherein the polypeptide has the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.

30

33. A peptide or polypeptide which comprises an antigenic amino acid sequence derived from the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.

35

- 123 -

34. The peptide or polypeptide of claim 33 which comprises at least a ten amino acid stretch which corresponds to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.

5

35. The peptide or polypeptide of claim 34 which comprises as a part of its amino acid sequence at least a fifteen amino acid stretch which corresponds to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.

10

36. The peptide or polypeptide of claim 35 further defined as comprising the amino acid sequence of SEQ ID NO:5.

15

~~37. An antibody immunoreactive with the peptide or polypeptide of any of claims 33-36.~~

20

38. The antibody of claim 37 wherein said antibody is a monoclonal antibody.

25

39. A method of screening substances as modulators of ileal/renal bile acid cotransport activity comprising the following steps:

30 obtaining a candidate substance; and

determining an effect of said candidate substance on said cotransport activity.

35

- 124 -

40. The method of claim 39 wherein activity is determined in recombinant cells.

5 41. The method of claim 39 wherein the cotransport substrates are (³H)-taurocholate and sodium ions.

42. A method of detecting ileal/renal bile acid cotransporter nucleic acid comprising the following steps:

15 obtaining a nucleic acid sample suspected of containing ileal/renal bile acid cotransporter nucleic acid; and

detecting the presence of ileal/renal bile acid cotransporter nucleic acid in said sample.

20

43. The method of claim 42, wherein said detecting comprises hybridizing the nucleic acid of said sample to a nucleic acid segment in accordance with any of claims 1-30.

25

44. The method of claim 43, wherein said detecting is further defined as comprising:

30 amplifying ileal/renal bile acid cotransporter nucleic acid sequences in said nucleic acid sample; and

35 detecting the presence of amplified ileal/renal bile acid cotransporter nucleic acid sequences in said nucleic acid sample.

- 125 -

45. The method of any of claims 42-44 wherein said nucleic acid sample is from a human subject and the nucleic acid segment is a sequence according to SEQ ID
5 NO:3.

46. A method of screening substances as modulators of ileal/renal bile acid cotransporter expression comprising
10 the following steps:

) obtaining a candidate substance;

15 exposing cells expressing a reporter gene under the control of an ileal or renal bile acid cotransporter promoter to said candidate substance; and

20 determining an effect of said candidate substance upon expression of said reporter gene.

) 47. The method of claim 46 wherein said reporter gene is *E. coli* beta-galactosidase or chloramphenicol
25 acetyltransferase.

48. A method of detecting heterozygous ileal/renal bile acid cotransporter gene alleles in a subject comprising
30 the following steps:

amplifying the ileal/renal bile acid cotransporter genes from said subject; and

- 126 -

subjecting the amplified nucleic acid segments to
denaturation followed by electrophoresis under
nondenaturing conditions.

5

49. The method of claim 48 wherein one of said
ileal/renal bile acid cotransporter gene alleles encodes
a serine at position 290.

10

50. The method of claim 48 wherein said amplifying is by
the polymerase chain reaction using oligonucleotides
having the sequences of SEQ ID NO:6 and SEQ ID NO:7 as
primers.

15

51. The method of claim 48 wherein said amplifying is by
the polymerase chain reaction using oligonucleotides
having the sequences of SEQ ID NO:8 and SEQ ID NO:9 as
20 primers.

1/17




FIG. 1A




FIG. 1B

SUBSTITUTE SHEET (RULE 26)

2/17




FIG. 2

SUBSTITUTE SHEET (RULE 26)

3/17




FIG. 3

4/17




FIG. 4

SUBSTITUTE SHEET (RULE 26)

5/17




FIG. 5B




FIG. 5A

SUBSTITUTE SHEET (RULE 26)

6/17




FIG. 6A




FIG. 6B

SUBSTITUTE SHEET (RULE 26)

7/17




FIG. 7B




FIG. 7A

SUBSTITUTE SHEET (RULE 26)

8/17

| | | |
|---------|---|-----|
| HUMAN | MNDPNSCVDNATVCSGASCVPESNFNNILSVVMSTVLTIALLVMFSMGCNVEIKK | 57 |
| HAMSTER | MNDSSICNPENATICCGDSCIAPESNFNAILSVVMSTVLTIALLVMFSMGCNVEIKK | |
| HUMAN | FLGHIKRPWGICVGLCQFGIMPLTGFI LSVAFDILPLQAVVLIIGCCPGGTASNI | 114 |
| HAMSTER | FLGHLLRRPWGIVVGLCQFGIMPLTGFI LSVAFGILFPVQAVVLIQGCCPGGTASNI | |
| HUMAN | LAYWVDGDMDLVSMTTCSTLLALGMMPLCLLIYTKMWVDSGSIVIPYDNIGTSLVA | 171 |
| HAMSTER | LAYWVDGDMDLVSMTTCSTLLALGMMPLCLFIYTKMWVDSGTIVIPYDSIGTSLVA | |
| HUMAN | LVVPVSI GMFVNHHKWPQAKIILKIGSIAGAILLVIAVVGILYQSAWIIAPKLWI | 228 |
| HAMSTER | LVLPVSI GMVYVNNHHKWPQAKIILKIGSIAGAILLVIAVVGILYQSAWTEPKLWI | |
| HUMAN | IGTIFPVAGYSLGELLARIAGLPWYRCRTVAFETGMONTQLCSTIVQLSFTPEELNV | 285 |
| HAMSTER | IGTIIPVAGYGLGFELARIAGQPWYRCRTVALETGLQNTQLCSTIVQLSFSPEDLNL | |
| HUMAN | VFTFPLIYSIFQLAFAAIFLGFYVAYKKCHGKNKAEIPESKENGTEPESFYKANGG | 342 |
| HAMSTER | VFTFPLIYSIFQLAFAAII LGLAVYVAYKKCHGKNNTFELQEKTDNEMEPRSSFQETNKG | |
| HUMAN | FQPDEK | 348 |
| HAMSTER | FQPDEK | |

FIG. 8

SUBSTITUTE SHEET (RULE 26)

9/17




FIG. 9

10/17




FIG. 10

11/17





FIG. 11A

FIG. 11B
SUBSTITUTE SHEET (RULE 26)

12/17




FIG. 12

SUBSTITUTE SHEET (RULE 26)

13/17




FIG. 13A




FIG. 13B

SUBSTITUTE SHEET (RULE 26)





FIG. 14

SUBSTITUTE SHEET (RULE 26)

15/17



WT →
MUT →
WT →

DS DNA →




FIG. 15

SUBSTITUTE SHEET (RULE 26)

16/17

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 1 | 1 | 5 | 3 | 1 | 4 | 4 |
| 4 | 2 | 3 | 4 | 7 | 6 | 7 | 8 | 9 |




FIG. 16

SUBSTITUTE SHEET (RULE 26)




FIG. 17

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/14431

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 38/17; C07K 14/435; C12N 15/00, 15/12

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 69.1, 7.2, 7.21, 172.3, 240.2, 320.1; 536/23.5, 24.3, 24.31, 24.33

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS and DIALOG (files 5,155,351,357,358) search terms: transporter, cotransporter, ileal, bile acid, sodium, mammal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------------------------|---|---|
| X ---- Y ---- A | PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, Volume 88, issued December 1991, B. Hagenbuch et al, "Functional expression cloning and characterization of the hepatocyte Na ⁺ /bile acid cotransport system", pages 10629-10633, especially Figure 2. | 1, 6-8, 39-43 ----- 44, 46-48 ----- 2-5, 9-38, 45, 49-51 |



Further documents are listed in the continuation of Box C.



See patent family annex.

| | |
|---|--|
| * Special categories of cited documents: | *T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| *A* document defining the general state of the art which is not considered to be of particular relevance | *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| *E* earlier document published on or after the international filing date | *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *&* document member of the same patent family |
| *O* document referring to an oral disclosure, use, exhibition or other means | |
| *P* document published prior to the international filing date but later than the priority date claimed | |

Date of the actual completion of the international search

31 MARCH 1995

Date of mailing of the international search report

12 APR 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

Marianne Porta Allen

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/14431**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/14431

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

435/6, 69.1, 7.2, 7.21, 172.3, 240.2, 320.1; 536/23.5, 24.3, 24.31, 24.33

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

- I. Claims 1-36, drawn to nucleic acids for the ileal/renal bile acid cotransporter and the cotransporter proteins, classified in at least Class 536, subclass 23.5, for example.
- II. Claims 37-38, drawn to antibodies, classified in at least Class 530, subclass 387.1, for example.
- III. Claims 39-41 and 46-47, drawn to methods of screening substances, classified in at least Class 435, subclass 7.1, for example.
- IV. Claims 42-45 and 48-51, drawn to methods of detection, classified in at least Class 435, subclass 6, for example.

The claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept. Note that PCT Rule 13 does not provide for multiple products or methods within a single application. Groups I and II are drawn to structurally different products and groups III and IV are drawn to methods having different goals, steps, and starting materials.

This Page is inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☒ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images problems checked, please do not report the problems to the IFW Image Problem Mailbox

THIS PAGE BLANK (USPTO)